

Supporting Information

**Metal-Free Alkene Carbooxygénéation Following Tandem Intramolecular
Alkoxylation/Claisen Rearrangement:
Stereospecific Access to Bridged [4.2.1] Lactones**

Long Li, Xin-Qi Zhu, Ying-Qi Zhang, Hao-Zhen Bu, Peng Yuan, Jinyu Chen, Jingyi Su,
Xianming Deng and Long-Wu Ye*

State Key Laboratory of Physical Chemistry of Solid Surfaces and Key Laboratory for
Chemical Biology of Fujian Province, College of Chemistry and Chemical Engineering,
Xiamen University, Xiamen 361005, China

E-mail: longwuye@xmu.edu.cn

Content	Page Number
General	2
More Reaction Condition, Scope and Mechanism Studies	3
Biological Tests	6
Preparation of Starting Materials	7
General Procedure: Brønsted Acid Catalysis	36
Crystal Data	64
HPLC Chromatograms	68
¹ H and ¹³ C NMR Spectra	77


General Information. Ethyl acetate (ACS grade), hexanes (ACS grade) and anhydrous 1,2-dichloroethane (ACS grade) were obtained commercially and used without further purification. Methylene chloride, tetrahydrofuran and diethyl ether were purified according to standard methods unless otherwise noted. Commercially available reagents were used without further purification. Ees are determined using HPLC on a chiral stationary phase. Reactions were monitored by thin layer chromatography (TLC) using silicycle pre-coated silica gel plates. Flash column chromatography was performed over silica gel (300-400 mesh). Infrared spectra were recorded on a Nicolet AVATER FTIR330 spectrometer as thin film and are reported in reciprocal centimeter (cm^{-1}). Mass spectra were recorded with Micromass QTOF2 Quadrupole/Time-of-Flight Tandem mass spectrometer using electron spray ionization.

^1H NMR spectra were recorded on a Bruker AV-400 spectrometer and a Bruker AV-500 spectrometer in chloroform-d₃. Chemical shifts are reported in ppm with the internal TMS signal at 0.0 ppm as a standard. The data is being reported as (s = singlet, d = doublet, t = triplet, m = multiplet or unresolved, brs = broad singlet, coupling constant(s) in Hz, integration).

^{13}C NMR spectra were recorded on a Bruker AV-400 spectrometer and a Bruker AV-500 spectrometer in chloroform-d₃. Chemical shifts are reported in ppm with the internal chloroform signal at 77.0 ppm as a standard.

More Reaction Condition, Scope and Mechanism Studies

1. Other reaction condition studies on the cascade cyclization of indolyl ynamide **1a**^a




Entry	Catalyst	Reaction conditions	Yield ^b (%)		
			2a	2aa	1a
1	AgOTf	DCE, 40 °C, 48 h	<1	30	50
2	AgNTf ₂	DCE, 40 °C, 48 h	<1	<1	>95
3	CF ₃ CO ₂ H	DCE, 40 °C, 48 h	<1	<1	<1
4	MsOH	DCE, 40 °C, 48 h	<1	<1	<1
5	TsOH	DCE, 40 °C, 48 h	<1	<1	<1
6	HNTf ₂	toluene, 40 °C, 48 h	28	26	<1
7	HNTf ₂	PhCl, 40 °C, 48 h	69	<1	<1
8	HNTf ₂	THF, 40 °C, 48 h	<1	<1	<1
9	HNTf ₂	CH ₃ CN, 40 °C, 48 h	44	12	<1
10 ^c	HNTf ₂	DCE, 40 °C, 24 h	80	<1	<1
11 ^d	HNTf ₂	DCE, 40 °C, 24 h	74	<1	<1

^a Reaction conditions: **1a** (0.1 mmol), catalyst (20 mol %), solvent (2 mL), 40 °C, in vials. ^b Measured by ¹H NMR using diethyl phthalate as the internal standard.


^c The reaction was performed in a flame-dried vial with dry DCE as the solvent and 1 equiv of H₂O as an additive. ^d The reaction was performed in a flame-dried vial with dry DCE as the solvent and 2 equiv of H₂O as an additive.

2. Almost no desired product was formed by employing substrates with other PG groups such as Me, Boc, Ac and benzyl, as these kinds of substrates are too reactive and may undergo many side reactions such as hydration reaction, dimerization reaction and decomposition under the acidic conditions.


3. [3,3] rearrangement vs [1,3] rearrangement:



4. We tried various chiral Brønsted acids such as chiral phosphoric acids and chiral phosphoric amides (see as followed), but found that they failed to catalyze this cascade cyclization (most of substrates were recovered).




5. Notably, after the reaction was finished (1 h), significant epimerization was observed if prolonging the reaction time.




6. A possible molecular model of transition state to explain the chirality induction (**2a** as an example) has been proposed. Notably, the indole moiety has to occupy the axial


position but not the equatorial position as the indolyl group and oxygen are on the same side of the double bond. In addition, the second chiral center of product **2a** should be induced by the first chiral center (*cis* configuration).




7. For the effects of other metal catalysts on catalyzing the conversion **2aa** into **2a**, see:



8. **2a** could not be converted into **2ai** in the presence of HNTf₂ and MeOH, and only **2a** was recovered. This result indicated that **2ai** should come from **2aa** but not **2a**.



9. Significant incorporation of ¹⁸O (>85%) into the product **2a** was observed in the presence of ¹⁸O-labelled water (10 equiv), indicating that the oxygen atom on the carbonyl group of **2a** originates from water.



Cell Viability Assay.

The cytotoxic effects of the indole-fused lactone compounds on human cancer cells (MDA-MB-231, A375, MCF-7, SK-GT-4 and KYSE-450) were investigated using a commercially available proliferation assay kit (Promega, US). Briefly, the cells were plated in 96-well culture plates at an appropriate density in culture medium and allowed to attach overnight. After treatment of vehicle (0.1% DMSO as control) or test compounds for indicated times and concentrations, 20 µL of MTS reaction solution (3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2- (4-sulfophenyl)-2H-tetrazolium, inner salt; MTS (a) and 100 µg/mL phenazine methosulfate; PES) was added to each well. The absorbance values were read at 490 nm wavelength with a spectrophotometer (Varioskan Flash, Thermo, US) after 1 to 4 hours incubation. The cell viability was calculated as: cell survival = (ODcompd. - ODblank)/(ODcontrol - ODblank)*100%.


Table S1. The cytotoxic effects of the newly synthesized indole-fused lactone compounds against cancer cells

Cmpd ID	Cell viability at 20 µM (%)				
	MDA-MB-231	A375	MCF-7	SK-GT-4	KYSE-450
2a	99.49	82.26	105.05	94.43	92.88
2b	100.43	87.91	109.52	93.46	85.22
2c	88.17	85.78	126.55	90.16	84.49
2d	90.54	95.18	127.82	91.23	80.40
2e	94.13	86.68	89.27	93.19	87.92
2f	98.84	86.09	124.54	90.07	80.71
2g	95.33	78.72	95.25	91.62	75.82
2h	114.83	99.59	92.34	101.12	83.63
2i	105.53	109.08	99.99	96.41	82.66
2j	112.04	92.08	71.80	102.95	79.56
2k	56.71	40.50	98.57	72.27	76.90
2l	54.71	48.00	108.09	93.58	75.83
2m	86.96	87.76	121.30	93.12	97.55
2n	107.95	103.52	112.91	102.15	101.09
2o	56.27	45.57	66.78	91.57	88.43
2t	95.42	86.75	119.05	97.59	99.96
2z	93.06	94.49	100.37	96.98	91.59
2ab	91.08	102.28	113.21	95.11	84.87
2ae	41.59	33.41	70.16	64.00	37.01
2af	91.12	96.02	32.77	91.72	88.98
2ah	88.27	91.21	103.63	91.85	90.31


Results are average of two experiments.

Experimental Section

Representative synthetic procedures for the preparation of indole-tethered ynamides **1**:¹⁻³




N-((2-((allyloxy)methyl)-1-tosyl-1*H*-indol-3-yl)ethynyl)-N-methylmethanesulfonamide (1a)



1a

Pale yellow solid (mp 110-111 °C). ¹H NMR (400 MHz, CDCl₃) δ 8.12 (d, *J* = 8.4 Hz, 1H), 7.94 (d, *J* = 8.4 Hz, 2H), 7.58 (d, *J* = 7.6 Hz, 1H), 7.44 – 7.32 (m, 1H), 7.32 – 7.24 (m, 1H), 7.18 (d, *J* = 8.0 Hz, 2H), 6.00 – 5.87 (m, 1H), 5.38 – 5.27 (m, 1H), 5.21 (dd, *J* = 10.4, 1.2 Hz, 1H), 5.02 (s, 2H), 4.06 (dt, *J* = 5.6, 1.2 Hz, 2H), 3.33 (s, 3H), 3.14 (s, 3H), 2.33 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 145.0, 139.3, 135.8, 135.7, 134.6, 129.6, 129.1, 127.4, 126.0, 123.8, 120.2, 117.2, 114.7, 107.5, 89.2, 71.2, 62.6, 60.7, 39.3, 37.0, 21.5; IR (neat): 2923, 2850, 2239(s), 1357(s), 1160, 1108, 576; HRESIMS Calcd for [C₂₃H₂₄N₂NaO₅S₂]⁺ (*M* + Na⁺) 495.1019, found 495.1008.


***N*-((2-((allyloxy)methyl)-5-methyl-1-tosyl-1*H*-indol-3-yl)ethynyl)-*N*-methylmethanesulfonamide (**1b**)**



1b

Pale yellow solid (mp 115–116 °C). ^1H NMR (400 MHz, CDCl_3) δ 7.99 (d, $J = 8.8$ Hz, 1H), 7.91 (d, $J = 8.0$ Hz, 2H), 7.35 (s, 1H), 7.22 – 7.12 (m, 3H), 6.03 – 5.81 (m, 1H), 5.30 (d, $J = 17.2$ Hz, 1H), 5.19 (d, $J = 10.4$ Hz, 1H), 4.99 (s, 2H), 4.05 (d, $J = 4.0$ Hz, 2H), 3.34 (s, 3H), 3.14 (s, 3H), 2.42 (s, 3H), 2.32 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 144.8, 139.4, 135.8, 134.6, 134.1, 133.6, 129.5, 129.3, 127.4, 127.3, 120.0, 117.1, 114.4, 107.3, 89.2, 71.1, 62.6, 60.9, 39.3, 37.0, 21.5, 21.2; IR (neat): 2924, 2850, 1774, 1612, 1491, 1362(s), 1147, 584; HRESIMS Calcd for $[\text{C}_{24}\text{H}_{26}\text{N}_2\text{NaO}_5\text{S}_2]^+$ ($\text{M} + \text{Na}^+$) 509.1175, found 509.1168.

***N*-((2-((allyloxy)methyl)-5-methoxy-1-tosyl-1*H*-indol-3-yl)ethynyl)-*N*-methylmethanesulfonamide (**1c**)**




1c

Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 8.00 (d, $J = 9.2$ Hz, 1H), 7.88 (d, $J = 8.4$ Hz, 2H), 7.16 (d, $J = 8.0$ Hz, 2H), 7.00 (d, $J = 2.4$ Hz, 1H), 6.96 (dd, $J = 9.2, 2.8$ Hz, 1H), 6.00 – 5.85 (m, 1H), 5.36 – 5.26 (m, 1H), 5.24 – 5.16 (m, 1H), 4.97 (s, 2H), 4.05 (dt, $J = 5.6, 1.6$ Hz, 2H), 3.83 (s, 3H), 3.33 (s, 3H), 3.13 (s, 3H), 2.31 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 156.8, 144.9, 139.6, 135.5, 134.5, 130.3, 130.2, 129.5, 127.2, 117.0,

115.6, 115.0, 107.5, 102.3, 89.4, 71.1, 62.5, 60.7, 55.6, 39.2, 36.9, 21.4; IR (neat): 2923, 2850, 2240(s), 1359(s), 1172, 1109, 999, 766; HRESIMS Calcd for $[C_{24}H_{26}N_2NaO_6S_2]^+$ ($M + Na^+$) 525.1124, found 525.1122.


***N*-((2-((allyloxy)methyl)-5-fluoro-1-tosyl-1*H*-indol-3-yl)ethynyl)-*N*-methylmethanesulfonamide (1d)**



1d

Pale yellow solid (mp 115–116 °C). 1H NMR (400 MHz, $CDCl_3$) δ 8.07 (dd, $J = 9.2, 4.0$ Hz, 1H), 7.90 (d, $J = 8.4$ Hz, 2H), 7.29 – 7.13 (m, 3H), 7.13 – 7.02 (m, 1H), 6.03 – 5.74 (m, 1H), 5.31 (dd, $J = 17.6, 1.6$ Hz, 1H), 5.21 (d, $J = 10.4$ Hz, 1H), 4.98 (s, 2H), 4.06 (d, $J = 5.6$ Hz, 2H), 3.33 (s, 3H), 3.13 (s, 3H), 2.32 (s, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 159.8 (d, $J = 242.2$ Hz), 145.2, 140.8, 135.3, 134.4, 132.0, 130.2 (d, $J = 9.7$ Hz), 129.6, 127.3, 117.2, 115.9 (d, $J = 9.7$ Hz), 113.9 (d, $J = 25.3$ Hz), 107.3 (d, $J = 4.0$ Hz), 105.7 (d, $J = 24.3$ Hz), 89.6, 71.2, 62.5, 60.0, 39.1, 37.0, 21.5; IR (neat): 2924, 2356(s), 1357(s), 1262, 1175, 760, 749; HRESIMS Calcd for $[C_{23}H_{23}FN_2NaO_5S_2]^+$ ($M + Na^+$) 513.0925, found 513.0909.


***N*-((2-((allyloxy)methyl)-5-chloro-1-tosyl-1*H*-indol-3-yl)ethynyl)-*N*-methylmethanesulfonamide (1e)**



1e

Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 8.04 (d, $J = 8.8$ Hz, 1H), 7.90 (d, $J = 8.4$ Hz, 2H), 7.53 (d, $J = 2.0$ Hz, 1H), 7.36 – 7.28 (m, 1H), 7.19 (d, $J = 8.4$ Hz, 2H), 5.99 – 5.85 (m, 1H), 5.37 – 5.26 (m, 1H), 5.21 (dd, $J = 10.4, 1.6$ Hz, 1H), 4.98 (s, 2H), 4.05 (dt, $J = 5.6, 1.2$ Hz, 2H), 3.33 (s, 3H), 3.14 (s, 3H), 2.34 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 145.3, 140.7, 135.4, 134.5, 134.2, 130.4, 129.8, 129.7, 127.4, 126.2, 119.8, 117.3, 115.9, 106.9, 89.6, 71.4, 62.5, 60.1, 39.3, 37.2, 21.6; IR (neat): 2926, 2238(s), 1360(s), 1265, 1175, 1111, 738; HRESIMS Calcd for $[\text{C}_{23}\text{H}_{23}\text{ClN}_2\text{NaO}_5\text{S}_2]^+$ ($\text{M} + \text{Na}^+$) 529.0629, found 529.0624.


***N*-((2-((allyloxy)methyl)-5-bromo-1-tosyl-1*H*-indol-3-yl)ethynyl)-*N*-methylmethanesulfonamide (1f)**



1f

Pale yellow solid (mp 130–131 °C). ^1H NMR (400 MHz, CDCl_3) δ 7.99 (d, $J = 8.8$ Hz, 1H), 7.90 (d, $J = 8.4$ Hz, 2H), 7.68 (d, $J = 1.6$ Hz, 1H), 7.44 (dd, $J = 8.8, 2.0$ Hz, 1H), 7.18 (d, $J = 8.4$ Hz, 2H), 6.03 – 5.78 (m, 1H), 5.31 (dd, $J = 17.6, 1.6$ Hz, 1H), 5.21 (d, $J = 10.4$ Hz, 1H), 4.98 (s, 2H), 4.05 (d, $J = 5.2$ Hz, 2H), 3.33 (s, 3H), 3.14 (s, 3H), 2.33 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 145.3, 140.5, 135.3, 134.5, 134.4, 130.7, 129.7, 128.8, 127.3, 122.8, 117.3(4), 117.2(8), 116.1, 106.7, 89.5, 71.3, 62.4, 60.0, 39.2, 37.1, 21.5; IR (neat): 2927, 2240(s), 1444, 1360(s), 1175, 999, 688, 581; HRESIMS Calcd for $[\text{C}_{23}\text{H}_{23}\text{BrN}_2\text{NaO}_5\text{S}_2]^+$ ($\text{M} + \text{Na}^+$) 573.0124, found 573.0129.


***N*-((2-((allyloxy)methyl)-1-tosyl-5-(trifluoromethyl)-1*H*-indol-3-yl)ethynyl)-*N*-methylmethanesulfonamide (1g)**



1g

Pale yellow solid (mp 150–151 °C). ^1H NMR (400 MHz, CDCl_3) δ 8.23 (d, $J = 8.8$ Hz, 1H), 7.95 (d, $J = 8.4$ Hz, 2H), 7.85 (s, 1H), 7.60 (d, $J = 8.8$ Hz, 1H), 7.21 (d, $J = 8.4$ Hz, 2H), 6.08 – 5.90 (m, 1H), 5.31 (dd, $J = 17.2, 1.6$ Hz, 1H), 5.22 (d, $J = 10.4$ Hz, 1H), 5.03 (s, 2H), 4.06 (d, $J = 5.6$ Hz, 2H), 3.35 (s, 3H), 3.15 (s, 3H), 2.35 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 145.5, 141.2, 137.2, 135.2, 134.3, 129.8, 128.8, 127.4, 126.2 (q, $J = 32.5$ Hz), 124.3 (q, $J = 270.0$ Hz), 122.5 (q, $J = 3.5$ Hz), 117.8 (q, $J = 4.0$ Hz), 117.4, 115.0, 107.4, 89.8, 71.3, 62.4, 59.8, 39.2, 37.2, 21.5; IR (neat): 2927, 2241(s), 1361, 1320(s), 1170, 1117, 665, 592; HRESIMS Calcd for $[\text{C}_{24}\text{H}_{23}\text{F}_3\text{N}_2\text{NaO}_5\text{S}_2]^+$ ($\text{M} + \text{Na}^+$) 563.0893, found 563.0888.

***N*-((2-((allyloxy)methyl)-5-cyano-1-tosyl-1*H*-indol-3-yl)ethynyl)-*N*-methylmethanesulfonamide (1h)**




1h

Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 8.21 (dd, $J = 8.8, 0.8$ Hz, 1H), 8.02 – 7.82 (m, 3H), 7.60 (dd, $J = 8.8, 1.6$ Hz, 1H), 7.22 (d, $J = 8.4$ Hz, 2H), 5.98 – 5.87 (m, 1H), 5.36 – 5.27 (m, 1H), 5.26 – 5.17 (m, 1H), 5.01 (s, 2H), 4.06 (dt, $J = 5.6, 1.2$ Hz, 2H), 3.35 (s, 3H), 3.15 (s, 3H), 2.36 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 145.7, 141.5, 137.4, 135.1, 134.2, 129.8, 129.2, 128.7, 127.5, 125.1, 118.9, 117.4, 115.5, 107.4, 107.0, 90.1, 71.4, 62.3, 59.4, 39.1, 37.3, 21.5; IR (neat): 2922, 2851, 2358, 2238(s), 1659, 1632,

1361(s), 1176, 737; HRESIMS Calcd for $[C_{24}H_{23}N_3NaO_5S_2]^+$ ($M + Na^+$) 520.0971, found 520.0972.


methyl 2-((allyloxy)methyl)-3-((*N*-methylmethysulfonamido)ethynyl)-1-tosyl-1*H*-indole-5-carboxylate (1i)



1i

Pale yellow oil. 1H NMR (400 MHz, $CDCl_3$) δ 8.26 (d, $J = 1.2$ Hz, 1H), 8.16 (d, $J = 8.8$ Hz, 1H), 8.03 (dd, $J = 8.8, 1.6$ Hz, 1H), 7.93 (d, $J = 8.4$ Hz, 2H), 7.19 (d, $J = 8.2$ Hz, 2H), 5.85 – 5.98 (m, 1H), 5.36 – 5.27 (m, 1H), 5.20 (dd, $J = 10.4, 1.2$ Hz, 1H), 5.01 (s, 2H), 4.06 (dd, $J = 4.4, 1.2$ Hz, 2H), 3.93 (s, 3H), 3.35 (s, 3H), 3.15 (s, 3H), 2.33 (s, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 166.8, 145.3, 140.8, 138.2, 135.2, 134.3, 129.6, 128.8, 127.4, 126.9, 125.8, 122.3, 117.2, 114.4, 107.7, 89.6, 71.2, 62.4, 59.9, 52.1, 39.2, 37.0, 21.5; IR (neat): 2923, 2367, 2240(s), 1717(s), 1358(s), 1289, 1174, 758; HRESIMS Calcd for $[C_{25}H_{26}N_2NaO_7S_2]^+$ ($M + Na^+$) 553.1074, found 553.1075.

***N*-(2-((allyloxy)methyl)-6-methyl-1-tosyl-1*H*-indol-3-yl)ethynyl)-*N*-methylmethanesulfonamide (1j)**




1j

Pale yellow oil. 1H NMR (400 MHz, $CDCl_3$) δ 7.95 – 7.87 (m, 3H), 7.45 (d, $J = 8.0$ Hz, 1H), 7.18 (d, $J = 8.0$ Hz, 2H), 7.10 (dd, $J = 8.0, 0.8$ Hz, 1H), 5.99 – 5.84 (m, 1H), 5.36 – 5.26 (m, 1H), 5.24 – 5.15 (m, 1H), 4.99 (s, 2H), 4.03 (dt, $J = 5.6, 1.2$ Hz, 2H), 3.33 (s,

3H), 3.13 (s, 3H), 2.49 (s, 3H), 2.34 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 144.8, 138.6, 136.2, 135.7, 134.5, 129.5, 127.2, 126.8, 125.3, 119.7, 117.0, 114.6, 107.5, 89.1, 71.0, 62.6, 60.8, 39.2, 36.9, 22.1, 21.5; IR (neat): 2927, 2241(s), 1361, 1326(s), 1176, 1117, 665, 592; HRESIMS Calcd for $[\text{C}_{24}\text{H}_{26}\text{N}_2\text{NaO}_5\text{S}_2]^+$ ($\text{M} + \text{Na}^+$) 509.1175, found 509.1173.


***N*-(2-((allyloxy)methyl)-6-methoxy-1-tosyl-1*H*-indol-3-yl)ethynyl)-*N*-methylmethanesulfonamide (1k)**



1k

Pale yellow oil. ^1H NMR (500 MHz, CDCl_3) δ 7.91 (d, $J = 8.0$ Hz, 2H), 7.65 (d, $J = 2.0$ Hz, 1H), 7.44 (d, $J = 9.0$ Hz, 1H), 7.18 (d, $J = 8.0$ Hz, 2H), 6.90 (dd, $J = 8.5, 2.0$ Hz, 1H), 5.99 – 5.83 (m, 1H), 5.34 – 5.26 (m, 1H), 5.19 (dd, $J = 5.5, 1.5$ Hz, 1H), 4.96 (s, 2H), 4.04 (dt, $J = 5.5, 1.5$ Hz, 2H), 3.88 (s, 3H), 3.32 (s, 3H), 3.13 (s, 3H), 2.33 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 158.9, 144.9, 138.1, 136.9, 135.7, 134.6, 129.6, 127.3, 122.8, 120.7, 117.0, 113.0, 107.5, 99.0, 89.1, 71.0, 62.7, 60.9, 55.8, 39.2, 36.9, 21.5; IR (neat): 2927, 2240(s), 1445, 1360(s), 1176, 960, 582; HRESIMS Calcd for $[\text{C}_{24}\text{H}_{26}\text{N}_2\text{NaO}_6\text{S}_2]^+$ ($\text{M} + \text{Na}^+$) 525.1124, found 525.1118.


***N*-(2-((allyloxy)methyl)-6-fluoro-1-tosyl-1*H*-indol-3-yl)ethynyl)-*N*-methylmethanesulfonamide (1l)**



1l

Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.92 (d, $J = 8.4$ Hz, 2H), 7.84 (dd, $J = 10.0, 2.0$ Hz, 1H), 7.50 (dd, $J = 8.4, 5.2$ Hz, 1H), 7.19 (d, $J = 8.4$ Hz, 2H), 7.11 – 6.86 (m, 1H), 6.01 – 5.80 (m, 1H), 5.35 – 5.27 (m, 1H), 5.24 – 5.17 (m, 1H), 4.96 (s, 2H), 4.04 (dt, $J = 5.6, 1.2$ Hz, 2H), 3.32 (s, 3H), 3.13 (s, 3H), 2.32 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 161.4 (d, $J = 242.7$ Hz), 145.2, 139.4 (d, $J = 3.8$ Hz), 135.8 (d, $J = 12.7$ Hz), 135.2, 134.4, 129.6, 127.3, 125.2, 121.1 (d, $J = 10.0$ Hz), 117.1, 112.2 (d, $J = 24.4$ Hz), 107.2, 102.0 (d, $J = 29.3$ Hz), 89.4, 71.0, 62.4, 60.2, 39.1, 36.9, 21.4; IR (neat): 2924, 2356(s), 1357(s), 1274, 1262, 1175, 764, 749; HRESIMS Calcd for $[\text{C}_{23}\text{H}_{23}\text{FN}_2\text{NaO}_5\text{S}_2]^+$ ($M + \text{Na}^+$) 513.0925, found 513.0923.


***N*-((2-((allyloxy)methyl)-6-chloro-1-tosyl-1*H*-indol-3-yl)ethynyl)-*N*-methylmethanesulfonamide (1m)**



1m

Pale yellow solid (mp 110–111 °C). ^1H NMR (400 MHz, CDCl_3) δ 8.04 (d, $J = 8.8$ Hz, 1H), 7.90 (d, $J = 8.4$ Hz, 2H), 7.53 (d, $J = 2.0$ Hz, 1H), 7.31 (dd, $J = 9.2, 2.0$ Hz, 1H), 7.19 (d, $J = 8.4$ Hz, 2H), 6.02 – 5.83 (m, 1H), 5.31 (dd, $J = 17.2, 1.2$ Hz, 1H), 5.21 (dd, $J = 10.4, 1.2$ Hz, 1H), 4.98 (s, 2H), 4.05 (d, $J = 5.6$ Hz, 2H), 3.33 (s, 3H), 3.14 (s, 3H), 2.34 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 145.3, 140.7, 135.4, 134.4, 134.1, 130.3, 129.8, 129.7, 127.3, 126.2, 119.8, 117.3, 115.8, 106.8, 89.5, 71.3, 62.5, 60.0, 39.2, 37.1, 21.5; IR (neat): 2926, 2238(s), 1445, 1360(s), 1265, 1175, 1111, 1000, 738, 583; HRESIMS Calcd for $[\text{C}_{23}\text{H}_{23}\text{ClN}_2\text{NaO}_5\text{S}_2]^+$ ($M + \text{Na}^+$) 529.0629, found 529.0629.


***N*-((2-((allyloxy)methyl)-6-bromo-1-tosyl-1*H*-indol-3-yl)ethynyl)-*N*-methylmethanesulfonamide (1n)**



1n

Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 8.30 (s, 1H), 7.91 (d, $J = 8.0$ Hz, 2H), 7.46 – 7.35 (m, 2H), 7.21 (d, $J = 8.0$ Hz, 2H), 6.02 – 5.78 (m, 1H), 5.30 (d, $J = 17.2$ Hz, 1H), 5.20 (d, $J = 10.4$ Hz, 1H), 4.97 (s, 2H), 4.04 (d, $J = 4.4$ Hz, 2H), 3.33 (s, 3H), 3.13 (s, 3H), 2.35 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 145.3, 139.7, 136.4, 135.4, 134.4, 129.7, 127.9, 127.4, 127.2, 121.4, 119.7, 117.7, 117.3, 107.3, 89.5, 71.3, 62.5, 60.2, 39.2, 37.1, 21.6; IR (neat): 2927, 2240(s), 1444, 1360(s), 1266, 1175, 1112, 999, 581; HRESIMS Calcd for $[\text{C}_{23}\text{H}_{23}\text{BrN}_2\text{NaO}_5\text{S}_2]^+$ ($\text{M} + \text{Na}^+$) 573.0124, found 573.0127.


methyl 2-((allyloxy)methyl)-3-((N-methylmethylsulfonamido)ethynyl)-1-tosyl-1H-indole-6-carboxylate (1o)



1o

Pale yellow oil. ^1H NMR (500 MHz, CDCl_3) δ 8.82 (s, 1H), 8.05 – 7.90 (m, 3H), 7.61 (d, $J = 8.5$ Hz, 1H), 7.20 (d, $J = 8.0$ Hz, 2H), 5.99 – 5.86 (m, 1H), 5.31 (dd, $J = 18.5, 1.0$ Hz, 1H), 5.21 (d, $J = 10.5$ Hz, 1H), 5.02 (s, 2H), 4.06 (d, $J = 5.5$ Hz, 2H), 3.97 (s, 3H), 3.34 (s, 3H), 3.14 (s, 3H), 2.33 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 167.0, 145.3, 142.0, 135.3, 135.2, 134.3, 132.6, 129.7, 127.7, 127.4, 124.8, 120.0, 117.3, 116.4, 107.2, 89.5, 71.3, 62.5, 60.1, 52.3, 39.2, 37.1, 21.5; IR (neat): 2923, 2240(s), 1717(s), 1358(s), 1174, 1161, 1089, 685; HRESIMS Calcd for $[\text{C}_{25}\text{H}_{26}\text{N}_2\text{NaO}_7\text{S}_2]^+$ ($\text{M} + \text{Na}^+$) 553.1074, found 553.1079.


***N*-((2-((allyloxy)methyl)-7-methyl-1-tosyl-1*H*-indol-3-yl)ethynyl)-*N*-methylmethanesulfonamide (**1p**)**



1p

Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.68 (d, $J = 8.4$ Hz, 2H), 7.39 (d, $J = 7.2$ Hz, 1H), 7.23 – 7.09 (m, 4H), 6.00 – 5.82 (m, 1H), 5.29 (dd, $J = 17.2, 1.6$ Hz, 1H), 5.17 (dd, $J = 10.4, 0.8$ Hz, 1H), 5.02 (s, 2H), 4.06 (d, $J = 5.6$ Hz, 2H), 3.32 (s, 3H), 3.13 (s, 3H), 2.51 (s, 3H), 2.35 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 144.4, 142.0, 137.8, 136.1, 134.4, 131.7, 130.0, 129.3, 127.2, 126.6, 124.7, 117.9, 117.0, 110.3, 90.0, 71.3, 64.5, 60.7, 39.1, 36.9, 22.1, 21.4; IR (neat): 2930, 2245(s), 1440, 1368(s), 1260, 1182, 1122, 736, 585; HRESIMS Calcd for $[\text{C}_{24}\text{H}_{26}\text{N}_2\text{NaO}_5\text{S}_2]^+$ ($\text{M} + \text{Na}^+$) 509.1175, found 509.1173.

***N*-((2-((allyloxy)methyl)-1-((4-bromophenyl)sulfonyl)-1*H*-indol-3-yl)ethynyl)-*N*-methylmethanesulfonamide (**1q**)**




1q

Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 8.09 (d, $J = 8.4$ Hz, 1H), 7.94 (d, $J = 8.8$ Hz, 2H), 7.59 (d, $J = 7.6$ Hz, 1H), 7.52 (d, $J = 8.8$ Hz, 2H), 7.43 – 7.35 (m, 1H), 7.34 – 7.28 (m, 1H), 6.00 – 5.84 (m, 1H), 5.30 (dd, $J = 17.6, 1.6$ Hz, 1H), 5.22 (d, $J = 10.4$ Hz, 1H), 5.00 (s, 2H), 4.05 (d, $J = 5.6$ Hz, 2H), 3.34 (s, 3H), 3.14 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 139.0, 137.4, 135.7, 134.4, 132.3, 129.2, 129.1, 128.9, 126.2, 124.2, 120.4, 117.3, 114.5, 108.2, 89.5, 71.2, 62.5, 60.5, 39.2, 37.0; IR (neat): 2923, 2239(s),

1357(s), 1170, 1160, 1108, 996, 576; HRESIMS Calcd for $[C_{22}H_{21}BrN_2NaO_5S_2]^+$ ($M + Na^+$) 558.9967, found 558.9974.


***N*-((2-((allyloxy)methyl)-1-(methylsulfonyl)-1*H*-indol-3-yl)ethynyl)-*N*-methylmethanesulfonamide (1r)**



1r

Pale yellow oil. 1H NMR (400 MHz, $CDCl_3$) δ 8.06 (d, $J = 8.4$ Hz, 1H), 7.65 (d, $J = 7.2$ Hz, 1H), 7.42 – 7.30 (m, 2H), 6.04 – 5.87 (m, 1H), 5.33 (dd, $J = 17.2, 1.6$ Hz, 1H), 5.21 (dd, $J = 10.4, 1.2$ Hz, 1H), 4.93 (s, 2H), 4.12 (d, $J = 5.6$ Hz, 2H), 3.36 (s, 3H), 3.30 (s, 3H), 3.16 (s, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 138.8, 136.0, 134.2, 128.8, 126.1, 123.9, 120.4, 117.6, 114.1, 106.6, 89.2, 71.5, 62.7, 60.4, 41.6, 39.2, 37.0; IR (neat): 32923, 2850, 2240(s), 1359(s), 1258, 1172, 1109, 999, 766; HRESIMS Calcd for $[C_{17}H_{20}N_2NaO_5S_2]^+$ ($M + Na^+$) 419.0706, found 419.0711.

***N*-((2-((but-3-en-2-yloxy)methyl)-1-tosyl-1*H*-indol-3-yl)ethynyl)-*N*-methylmethanesulfonamide (1s)**




1s

Pale yellow oil. 1H NMR (500 MHz, $CDCl_3$) δ 8.06 (d, $J = 8.5$ Hz, 1H), 7.96 (d, $J = 8.5$ Hz, 2H), 7.57 (d, $J = 7.5$ Hz, 1H), 7.35 – 7.30 (m, 1H), 7.29 – 7.23 (m, 1H), 7.18 (d, $J = 8.0$ Hz, 2H), 5.91 – 5.79 (m, 1H), 5.32 (d, $J = 17.0$ Hz, 1H), 5.19 (d, $J = 10.5$ Hz, 1H), 5.03 (d, $J = 11.5$ Hz, 1H), 4.84 (d, $J = 11.5$ Hz, 1H), 4.16 – 4.05 (m, 1H), 3.32 (s, 3H),

3.13 (s, 3H), 2.31 (s, 3H), 1.25 (d, $J = 6.5$ Hz, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 144.9, 140.0, 135.6(7), 135.6(5), 129.5, 129.1, 127.3, 125.8, 123.7, 120.1, 116.1, 114.5, 107.0, 89.1, 77.1, 60.8, 60.7, 39.2, 36.8, 21.5, 21.1; IR (neat): 2930, 2240(s), 1451, 1360(s), 1176, 1165, 997, 747, 578; HRESIMS Calcd for $[\text{C}_{24}\text{H}_{26}\text{N}_2\text{NaO}_5\text{S}_2]^+$ ($\text{M} + \text{Na}^+$) 509.1175, found 509.1168.


N-methyl-N-((2-((2-phenylallyl)oxy)methyl)-1-tosyl-1*H*-indol-3-yl)ethynylmethanesulfonamide (1t)



1t

Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 8.11 (d, $J = 8.4$ Hz, 1H), 7.89 (d, $J = 8.4$ Hz, 2H), 7.58 (d, $J = 7.6$ Hz, 1H), 7.53 – 7.45 (m, 2H), 7.40 – 7.22 (m, 5H), 7.11 (d, $J = 8.4$ Hz, 2H), 5.57 (s, 1H), 5.42 (d, $J = 1.2$ Hz, 1H), 5.09 (s, 2H), 4.45 (s, 2H), 3.23 (s, 3H), 3.02 (s, 3H), 2.30 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 144.9, 143.9, 139.2, 138.8, 135.8, 135.5, 129.6, 129.1, 128.4, 127.8, 127.3, 126.0(4), 125.9(7), 123.8, 120.3, 114.7, 114.4, 107.7, 89.3, 72.1, 62.7, 60.7, 39.1, 36.8, 21.5; IR (neat): 2927, 2868, 2240(s), 1596, 1445, 1360(s), 1176, 577, 590; HRESIMS Calcd for $[\text{C}_{29}\text{H}_{28}\text{N}_2\text{NaO}_5\text{S}_2]^+$ ($\text{M} + \text{Na}^+$) 571.1332, found 571.1339.


N-methyl-N-((6-methyl-2-((2-phenylallyl)oxy)methyl)-1-tosyl-1*H*-indol-3-yl)ethynylmethanesulfonamide (1u)



1u

Pale yellow oil. ^1H NMR (500 MHz, CDCl_3) δ 7.95 (s, 1H), 7.90 (d, $J = 8.5$ Hz, 2H), 7.52 – 7.45 (m, 3H), 7.35 – 7.29 (m, 2H), 7.29 – 7.24 (m, 1H), 7.14 – 7.08 (m, 3H), 5.59 (d, $J = 0.5$ Hz, 1H), 5.43 (d, $J = 1.0$ Hz, 1H), 5.08 (s, 2H), 4.46 (s, 2H), 3.23 (s, 3H), 3.03 (s, 3H), 2.50 (s, 3H), 2.30 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 144.7, 143.8, 138.7, 138.5, 136.2, 135.6, 135.5, 129.5, 128.3, 127.7, 127.1, 126.8, 126.0, 125.3, 119.8, 114.6, 114.2, 107.6, 89.1, 71.9, 62.6, 60.7, 39.1, 36.7, 22.0, 21.4; IR (neat): 2923, 2239(s), 1446, 1360(s), 1175, 1111, 998, 579; HRESIMS Calcd for $[\text{C}_{30}\text{H}_{30}\text{N}_2\text{NaO}_5\text{S}_2]^+$ ($\text{M} + \text{Na}^+$) 585.1488, found 585.1491.


***N*-((5-chloro-2-(((2-phenylallyl)oxy)methyl)-1-tosyl-1*H*-indol-3-yl)ethynyl)-*N*-methylmethanesulfonamide (1v)**



1v

Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 8.03 (d, $J = 8.8$ Hz, 1H), 7.86 (d, $J = 8.4$ Hz, 2H), 7.53 (d, $J = 2.0$ Hz, 1H), 7.47 (d, $J = 6.8$ Hz, 2H), 7.35 – 7.20 (m, 4H), 7.10 (d, $J = 8.0$ Hz, 2H), 5.57 (s, 1H), 5.41 (s, 1H), 5.05 (s, 2H), 4.45 (s, 2H), 3.23 (s, 3H), 3.02 (s, 3H), 2.29 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 145.2, 143.7, 140.5, 138.6, 135.1, 134.0, 130.3, 129.7, 129.6, 128.3, 127.8, 127.3, 126.1, 126.0, 119.8, 115.8, 114.5, 107.0, 89.5, 72.2, 62.5, 59.9, 39.1, 36.9, 21.5; IR (neat): 2926, 2238(s), 1445, 1359(s), 1175, 1113, 999, 584; HRESIMS Calcd for $[\text{C}_{29}\text{H}_{27}\text{ClN}_2\text{NaO}_5\text{S}_2]^+$ ($\text{M} + \text{Na}^+$) 605.0942, found 605.0956.


***N*-((6-bromo-2-(((2-phenylallyl)oxy)methyl)-1-tosyl-1*H*-indol-3-yl)ethynyl)-*N*-methylmethanesulfonamide (1w)**



1w

Pale yellow solid (mp 120-121 °C). ^1H NMR (500 MHz, CDCl_3) δ 7.99 (d, $J = 9.0$ Hz, 1H), 7.87 (d, $J = 8.5$ Hz, 2H), 7.70 (d, $J = 1.5$ Hz, 1H), 7.52 – 7.46 (m, 2H), 7.45 (dd, $J = 9.0, 2.0$ Hz, 1H), 7.35 – 7.23 (m, 3H), 7.11 (d, $J = 8.0$ Hz, 2H), 5.59 (s, 1H), 5.42 (d, $J = 1.5$ Hz, 1H), 5.07 (s, 2H), 4.46 (s, 2H), 3.24 (s, 3H), 3.03 (s, 3H), 2.30 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 145.2, 143.7, 140.4, 138.6, 135.2, 134.4, 130.8, 129.6, 128.8, 128.3, 127.8, 127.3, 126.0, 122.9, 117.3, 116.1, 114.5, 106.8, 89.6, 72.2, 62.5, 59.9, 39.1, 36.9, 21.5; IR (neat): 2927, 2240(s), 1596, 1445, 1360(s), 1176, 1113, 999, 667; HRESIMS Calcd for $[\text{C}_{29}\text{H}_{27}\text{BrN}_2\text{NaO}_5\text{S}_2]^+$ ($\text{M} + \text{Na}^+$) 649.0437, found 649.0451.


N-methyl-N-((2-((2-(*p*-tolyl)allyl)oxy)methyl)-1-tosyl-1*H*-indol-3-yl)ethynylmethanesulfonamide (1x)



1x

Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 8.11 (d, $J = 8.4$ Hz, 1H), 7.89 (d, $J = 8.4$ Hz, 2H), 7.62 – 7.55 (m, 1H), 7.41 – 7.33 (m, 3H), 7.31 – 7.27 (m, 1H), 7.16 – 7.06 (m, 4H), 5.53 (s, 1H), 5.37 (d, $J = 1.2$ Hz, 1H), 5.08 (s, 2H), 4.43 (s, 2H), 3.23 (s, 3H), 3.03 (s, 3H), 2.32 (s, 3H), 2.30 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 144.8, 143.7, 139.3, 137.5, 135.9, 135.8, 135.6, 129.5, 129.1, 129.0, 127.3, 125.9(3), 125.9(1), 123.8, 120.3, 114.7, 113.5, 107.6, 89.3, 72.1, 62.7, 60.7, 39.1, 36.8, 21.5, 21.1; IR (neat): 2923, 2240(s), 1446, 1365(s), 1170, 1111, 998, 580; HRESIMS Calcd for $[\text{C}_{30}\text{H}_{30}\text{N}_2\text{NaO}_5\text{S}_2]^+$ ($\text{M} + \text{Na}^+$) 585.1488, found 585.1491.


***N*-((2-(((2-(4-chlorophenyl)allyl)oxy)methyl)-1-tosyl-1*H*-indol-3-yl)ethynyl)-*N*-methylmethanesulfonamide (**1y**)**



1y

Pale yellow oil. ^1H NMR (500 MHz, CDCl_3) δ 8.08 (d, $J = 7.5$ Hz, 1H), 7.84 (d, $J = 7.0$ Hz, 2H), 7.57 (d, $J = 7.0$ Hz, 1H), 7.48 – 7.16 (m, 6H), 7.07 (d, $J = 7.0$ Hz, 2H), 5.55 (s, 1H), 5.41 (s, 1H), 5.05 (s, 2H), 4.43 (s, 2H), 3.25 (s, 3H), 3.06 (s, 3H), 2.28 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 144.9, 142.9, 139.1, 137.1, 135.8, 135.5, 133.5, 129.5, 129.0, 128.4, 127.5, 127.2, 126.0, 123.8, 120.2, 115.2, 114.7, 107.7, 89.4, 72.2, 62.7, 60.6, 39.1, 36.9, 21.5; IR (neat): 2932, 2250(s), 1443, 1370(s), 1260, 1182, 1122, 736, 575; HRESIMS Calcd for $[\text{C}_{29}\text{H}_{27}\text{ClN}_2\text{NaO}_5\text{S}_2]^+$ ($\text{M} + \text{Na}^+$) 605.0942, found 605.0956.

***N*-methyl-*N*-((2-(((2-methylallyl)oxy)methyl)-1-tosyl-1*H*-indol-3-yl)ethynyl)methanesulfonamide (**1z**)**




1z

Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 8.11 (d, $J = 8.4$ Hz, 1H), 7.93 (d, $J = 8.4$ Hz, 2H), 7.58 (dd, $J = 7.6, 0.4$ Hz, 1H), 7.39 – 7.33 (m, 1H), 7.31 – 7.27 (m, 1H), 7.17 (d, $J = 8.0$ Hz, 2H), 5.03 (d, $J = 1.2$ Hz, 1H), 5.00 (s, 2H), 4.93 (d, $J = 0.4$ Hz, 1H), 3.97 (s, 2H), 3.33 (s, 3H), 3.13 (s, 3H), 2.33 (s, 3H), 1.77 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 144.9, 142.1, 139.5, 135.8, 135.7, 129.6, 129.2, 127.4, 125.9, 123.8, 120.2, 114.7, 112.1, 107.5, 89.2, 74.1, 62.6, 60.8, 39.2, 36.9, 21.5, 19.6; IR (neat): 2923, 2239(s), 1446,


1360(s), 1170, 1111, 1089, 998, 579; HRESIMS Calcd for $[C_{24}H_{26}N_2NaO_5S_2]^+$ ($M + Na^+$) 509.1175, found 509.1182.

N-((2-((allyloxy)methyl)benzofuran-3-yl)ethynyl)-N-methylmethanesulfonamide (3a)




Compound **3a** was prepared according to the above known procedures.¹⁻³ Pale yellow oil. 1H NMR (400 MHz, $CDCl_3$) δ 7.64 – 7.56 (m, 1H), 7.51 – 7.43 (m, 1H), 7.37 – 7.26 (m, 2H), 6.02 – 5.88 (m, 1H), 5.41 – 5.30 (m, 1H), 5.28 – 5.19 (m, 1H), 4.71 (s, 2H), 4.11 (dt, $J = 5.6, 1.6$ Hz, 2H), 3.35 (s, 3H), 3.16 (s, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 157.3, 154.3, 134.1, 128.2, 125.5, 123.3, 120.3, 117.9, 111.6, 102.8, 88.8, 71.5, 62.7, 59.2, 39.3, 36.9; IR (neat): 2922, 2851, 2239(s), 1469, 1356(s), 1158, 945, 747; HRESIMS Calcd for $[C_{16}H_{17}NNaO_4S]^+$ ($M + Na^+$) 342.0770, found 342.0770.

N-((2-((allyloxy)methyl)-1-tosyl-1*H*-pyrrol-3-yl)ethynyl)-N-methylmethanesulfonamide (3b)



Compound **3b** was prepared according to the above known procedures.¹⁻⁴ Pale yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.82 (d, *J* = 8.4 Hz, 2H), 7.32 – 7.22 (m, 3H), 6.27 (d, *J* = 3.2 Hz, 1H), 5.84 – 5.69 (m, 1H), 5.25 – 5.08 (m, 2H), 4.72 (s, 2H), 3.84 (dt, *J* = 5.6, 1.2 Hz, 2H), 3.24 (s, 3H), 3.06 (s, 3H), 2.39 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 145.0, 135.9, 134.5, 134.3, 129.6, 127.6, 123.2, 116.9, 114.0, 111.5, 85.7, 70.6, 62.3, 61.1, 39.1, 36.8, 21.5; IR (neat): 2926, 2238(s), 1445, 1360(s), 1265, 1175, 1111, 1000, 738, 583; HRESIMS Calcd for [C₁₉H₂₂N₂NaO₅S₂]⁺ (M + Na⁺) 445.0862, found 445.0863.


N-((2-((allyloxy)methyl)-4,5-dimethoxyphenyl)ethynyl)-*N*-methylmethanesulfonamide (**3c**)



Compound **3c** was prepared according to the above known procedures.¹⁻³ Pale yellow solid (mp 100-101 °C). ¹H NMR (500 MHz, CDCl₃) δ 6.97 (s, 1H), 6.88 (s, 1H), 6.06 – 5.90 (m, 1H), 5.31 (dd, *J* = 17.5, 1.5 Hz, 1H), 5.20 (dd, *J* = 10.0, 1.0 Hz, 1H), 4.59 (s,

2H), 4.06 (t, J = 1.0 Hz, 2H), 3.90 (s, 3H), 3.86 (s, 3H), 3.29 (s, 3H), 3.12 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 149.4, 148.0, 134.8, 133.6, 117.1, 114.4, 113.1, 111.1, 85.7, 71.3, 70.1, 67.3, 56.0, 55.9, 39.2, 36.7; IR (neat): 2927, 2240, 1596, 1445, 1360(s), 1176, 1088, 960, 590; HRESIMS Calcd for $[\text{C}_{16}\text{H}_{21}\text{NNaO}_5\text{S}]^+$ ($\text{M} + \text{Na}^+$) 362.1033, found 362.1035.


(E)-N-((2-((but-2-en-1-yloxy)methyl)-1-tosyl-1*H*-indol-3-yl)ethynyl)-*N*-methylmethanesulfonamide (3d)



3d


Compound **3d** was prepared according to the general procedures for the synthesis of ynamides **1**.¹⁻³ Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 8.13 (d, J = 8.4 Hz, 1H), 7.93 (d, J = 8.4 Hz, 2H), 7.66 – 7.51 (m, 1H), 7.41 – 7.32 (m, 1H), 7.30 – 7.24 (m, 1H), 7.17 (d, J = 8.0 Hz, 2H), 5.84 – 5.65 (m, 1H), 5.65 – 5.49 (m, 1H), 4.98 (s, 2H), 3.98 (d, J = 6.4 Hz, 2H), 3.33 (s, 3H), 3.13 (s, 3H), 2.32 (s, 3H), 1.72 (dd, J = 6.4, 1.2 Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 144.8, 139.4, 135.8, 135.7, 129.5(4), 129.4(6), 129.0, 127.3, 125.8, 123.7, 120.1, 114.6, 107.3, 89.2, 70.8, 62.3, 60.6, 39.2, 36.8, 21.4, 17.7; IR (neat): 2930, 2245(s), 1360, 1107, 1090, 748, 580; HRESIMS Calcd for $[\text{C}_{24}\text{H}_{26}\text{N}_2\text{NaO}_5\text{S}_2]^+$ ($\text{M} + \text{Na}^+$) 509.1175, found 509.1179.

***N*-allyl-*N*-((3-((*N*-methylmethysulfonamido)ethynyl)-1-tosyl-1*H*-indol-2-yl)methyl)methanesulfonamide (3e)**




Compound **3e** was prepared according to the above known procedures.¹⁻³ Pale yellow oil. ¹H NMR (500 MHz, CDCl₃) δ 8.14 (d, *J* = 8.0 Hz, 1H), 7.62 (d, *J* = 8.0 Hz, 2H), 7.57 (d, *J* = 7.5 Hz, 1H), 7.43 – 7.34 (m, 1H), 7.33 – 7.27 (m, 1H), 7.19 (d, *J* = 8.0 Hz, 2H), 5.83 – 5.67 (m, 1H), 5.14 (d, *J* = 17.0 Hz, 1H), 5.07 (d, *J* = 10.0 Hz, 1H), 4.98 (s, 2H), 3.90 (d, *J* = 6.5 Hz, 2H), 3.35 (s, 3H), 3.16 (s, 3H), 2.96 (s, 3H), 2.33 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 145.5, 136.9, 136.4, 134.8, 132.5, 130.1, 130.0, 126.5, 126.2, 124.5, 120.3, 118.9, 115.2, 109.2, 91.0, 60.2, 50.3, 44.0, 39.9, 39.2, 37.2, 21.5; IR (neat): 2926, 2235(s), 1440, 1363(s), 1265, 1175, 1111, 1000, 738, 585; HRESIMS Calcd for [C₂₄H₂₇N₃NaO₆S₃]⁺ (M + Na⁺) 572.0954, found 572.0956.

***N*-((2-((allylthio)methyl)-1-tosyl-1*H*-indol-3-yl)ethynyl)-*N*-methylmethanesulfonamide (3f)**



Compound **3f** was prepared according to the above known procedures.¹⁻³ ¹H NMR (500 MHz, CDCl₃) δ 8.04 (d, *J* = 8.5 Hz, 1H), 7.79 (d, *J* = 8.5 Hz, 2H), 7.53 (dd, *J* = 8.0, 1.0 Hz, 1H), 7.34 – 7.23 (m, 2H), 7.18 (d, *J* = 8.1 Hz, 2H), 5.96 – 5.78 (m, 1H), 5.30 – 5.20 (m, 1H), 5.16 – 5.04 (m, 1H), 4.28 (s, 2H), 3.33 (s, 3H), 3.29 (d, *J* = 7.0 Hz, 2H), 3.15 (s, 3H), 2.31 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 145.1, 141.7, 135.8, 135.4, 134.2, 129.7, 129.4, 126.8, 125.4, 124.0, 119.7, 117.0, 114.7, 105.6, 89.6, 60.8, 39.2, 37.0, 35.3, 27.7, 21.4; IR (neat): 2930, 2250(s), 1365, 1127, 1090, 750, 590; HRESIMS Calcd for [C₂₃H₂₄N₂NaO₄S₃]⁺ (M + Na⁺) 511.0790, found 511.0796.


***N*-((2-(allyloxy)ethyl)-1-tosyl-1*H*-indol-3-yl)ethynyl)-*N*-methylmethanesulfonamide (**3g**)**



3g

Compound **3g** was prepared according to the general procedures for the synthesis of ynamides **1**.¹⁻³ Pale yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.15 (d, *J* = 6.8 Hz, 1H), 7.62 (d, *J* = 6.8 Hz, 2H), 7.53 (dd, *J* = 6.0, 0.4 Hz, 1H), 7.36 – 7.21 (m, 2H), 7.14 (d, *J* = 6.4 Hz, 2H), 5.96 – 5.80 (m, 1H), 5.32 – 5.22 (m, 1H), 5.14 (dd, *J* = 8.0, 1.2 Hz, 1H), 4.01 (dt, *J* = 4.4, 0.8 Hz, 2H), 3.81 (t, *J* = 5.6 Hz, 2H), 3.49 (t, *J* = 5.6 Hz, 2H), 3.29 (s, 3H), 3.12 (s, 3H), 2.27 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 145.1, 141.6, 136.0, 135.6, 134.8, 129.9(0), 129.8(6), 126.3, 125.1, 124.0, 119.5, 116.6, 114.8, 106.0, 89.0, 71.6, 69.4, 60.8, 39.3, 36.7, 28.8, 21.5; IR (neat): 2931, 2241(s), 1359, 1107, 1089, 748, 577; HRESIMS Calcd for [C₂₄H₂₆N₂NaO₅S₂]⁺ (M + Na⁺) 509.1175, found 509.1179.


***N*-((2-((allyloxy)methyl)phenyl)ethynyl)-*N*-methylmethanesulfonamide (**3h**)**



3h

Compound **3h** was prepared according to the general procedures for the synthesis of ynamides **1**.¹⁻³ Pale yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.45 (d, 1H, J = 7.6 Hz), 7.41 – 7.36 (m, 1H), 7.32 – 7.26 (m, 1H), 7.25 – 7.19 (m, 1H), 6.02 – 5.91 (m, 1H), 5.35 – 5.27 (m, 1H), 5.24 – 5.17 (m, 1H), 4.63 (s, 2H), 4.09 – 4.06 (m, 2H), 3.29 (s, 3H), 3.11 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 139.5, 134.7, 131.3, 127.9, 127.8, 127.2, 121.1, 116.9, 87.3, 71.3, 70.2, 67.4, 39.0, 36.7; IR (neat): 3016, 2931, 2856, 2235, 1360, 1163, 959, 779, 516; HRESIMS Calcd for [C₁₄H₁₇NNaO₃S]⁺ (M + Na⁺) 302.0821, found 302.0825.

(S)-N-((2-((allyloxy)methyl)-1-tosyl-1*H*-indol-3-yl)ethynyl)-N-(1-phenylethyl)methanesulfonamide (5a)




5a


Compound **5a** was prepared according to the general procedures for the synthesis of ynamides **1**.¹⁻³ Pale yellow oil. [α]_D²⁰ = -246.7 °(c = 1.0, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 8.14 (d, J = 8.4 Hz, 1H), 7.96 (d, J = 8.4 Hz, 2H), 7.56 – 7.47 (m, 3H), 7.44 – 7.33 (m, 4H), 7.33 – 7.25 (m, 1H), 7.19 (d, J = 8.0 Hz, 2H), 6.00 – 5.82 (m, 1H), 5.33 – 5.22 (m, 2H), 5.17 (dd, J = 10.8, 1.6 Hz, 1H), 5.00 (d, J = 0.8 Hz, 2H), 4.01 (dt, J = 5.6, 1.2 Hz, 2H), 2.81 (s, 3H), 2.34 (s, 3H), 1.80 (d, J = 7.2 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 144.9, 139.6, 139.3, 135.9, 135.8, 134.6, 129.8, 129.3, 128.8, 128.7, 127.4, 127.0, 125.9, 123.8, 120.2, 117.0, 114.7, 107.8, 85.8, 71.2, 64.9, 62.8, 59.1, 39.1, 21.5,

19.9; IR (neat): 2925, 2854, 2239(s), 1451, 1361, 1166, 1094, 577; HRESIMS Calcd for $[C_{30}H_{30}N_2NaO_5S_2]^+$ ($M + Na^+$) 585.1488, found 585.1491.

Representative synthetic procedures for the preparation of chiral ynamides 5b-5i:^{3f}




(S)-3-((2-((allyloxy)methyl)-1-tosyl-1*H*-indol-3-yl)ethynyl)-4-phenyloxazolidin-2-one (5b)



5b

Pale yellow oil. $[\alpha]_D^{20} = -41.5$ °(c = 1.0, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 8.06 (d, *J* = 8.4 Hz, 1H), 7.89 (d, *J* = 8.4 Hz, 2H), 7.58 – 7.37 (m, 5H), 7.36 – 7.22 (m, 2H), 7.21 – 7.08 (m, 3H), 5.93 – 5.66 (m, 1H), 5.33 – 5.07 (m, 3H), 4.94 – 4.70 (m, 3H), 4.34 (dd, *J* = 8.4, 7.6 Hz, 1H), 3.80 (d, *J* = 5.6 Hz, 2H), 2.31 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 155.2, 144.9, 139.1, 135.9, 135.8, 135.7, 134.6, 129.7, 129.5, 129.4, 128.9, 127.4, 127.0, 125.8, 123.7, 120.3, 116.9, 114.5, 107.3, 84.3, 70.9, 70.8, 64.0, 62.5, 62.3, 21.5; IR (neat): 2920, 2257(s), 1779(s), 1374, 1176, 1087, 575; HRESIMS Calcd for [C₃₀H₂₆N₂NaO₅S]⁺ ($M + Na^+$) 549.1455, found 549.1458.


(S)-3-((2-((allyloxy)methyl)-1-tosyl-1*H*-indol-3-yl)ethynyl)-4-benzhydryloxazolidin-2-one (5c)



5c

Pale yellow solid (mp 140-141°C). $[\alpha]_D^{20} = -30.5^\circ$ (c = 1.0, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 8.16 (d, *J* = 8.4 Hz, 1H), 7.97 (d, *J* = 8.4 Hz, 2H), 7.47 (d, *J* = 7.6 Hz, 1H), 7.42 – 7.22 (m, 11H), 7.18 (d, *J* = 8.4 Hz, 2H), 7.15 – 7.04 (m, 1H), 6.05 – 5.86 (m, 1H), 5.33 (d, *J* = 17.2 Hz, 1H), 5.21 (d, *J* = 10.4 Hz, 1H), 5.11 – 4.83 (m, 3H), 4.56 (d, *J* = 5.2 Hz, 2H), 4.35 – 4.21 (m, 1H), 4.05 (d, *J* = 5.2 Hz, 2H), 2.31 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 155.4, 144.8, 139.2, 139.1, 138.4, 135.6, 135.5, 134.4, 129.4, 128.9, 128.7, 128.3, 128.1, 127.5, 127.3, 127.2, 125.7, 123.5, 120.4, 116.9, 114.3, 107.4, 84.6, 70.9, 66.5, 64.5, 62.4, 59.8, 53.2, 21.3; IR (neat): 2961, 2923, 2250(s), 1787(s), 1731, 1210, 1170, 580; HRESIMS Calcd for [C₃₇H₃₂N₂NaO₅S]⁺ (M + Na⁺) 639.1924, found 639.1925.

(S)-3-((2-((allyloxy)methyl)-1-tosyl-1H-indol-3-yl)ethynyl)-4-(tert-butyl)oxazolidin-2-one (5d)




5d

Pale yellow solid (mp 135-136°C). $[\alpha]_D^{20} = -20.7^\circ$ (c = 1.0, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 8.12 (d, *J* = 8.4 Hz, 1H), 7.94 (d, *J* = 8.4 Hz, 2H), 7.60 (d, *J* = 7.6 Hz, 1H), 7.42 – 7.32 (m, 1H), 7.31 – 7.23 (m, 1H), 7.17 (d, *J* = 8.4 Hz, 2H), 6.02 – 5.85 (m, 1H), 5.30 (dd, *J* = 17.2, 1.6 Hz, 1H), 5.19 (dd, *J* = 10.4, 1.2 Hz, 1H), 5.10 – 4.94 (m, 2H), 4.44 (t, *J* = 9.2 Hz, 1H), 4.27 (dd, *J* = 9.2, 5.2 Hz, 1H), 4.06 (d, *J* = 5.6 Hz, 2H), 3.88 (dd, *J* = 8.8, 5.2 Hz, 1H), 2.32 (s, 3H), 1.11 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 156.3, 144.9,

139.2, 135.8, 135.7, 134.6, 129.5, 129.1, 127.4, 125.9, 123.8, 120.3, 117.0, 114.6, 107.7, 86.6, 71.2, 66.2, 65.5, 63.3, 62.6, 34.9, 25.3, 21.5; IR (neat): 2967, 2256(s), 1773(s), 1371, 1187, 1137, 662, 584; HRESIMS Calcd for $[C_{28}H_{30}N_2NaO_5S]^+$ ($M + Na^+$) 529.1768, found 529.1771.


(*S*)-3-((2-((allyloxy)methyl)-5-methyl-1-tosyl-1*H*-indol-3-yl)ethynyl)-4-(*tert*-butyl)oxazolidin-2-one (5e)



5e

Pale yellow solid (mp 142-143°C). $[\alpha]_D^{20} = -10.5^\circ$ ($c = 1.0, CHCl_3$). 1H NMR (400 MHz, $CDCl_3$) δ 7.98 (d, $J = 8.4$ Hz, 1H), 7.91 (d, $J = 8.4$ Hz, 2H), 7.37 (s, 1H), 7.16 (d, $J = 8.4$ Hz, 3H), 6.00 – 5.83 (m, 1H), 5.29 (dd, $J = 17.2, 1.6$ Hz, 1H), 5.18 (d, $J = 10.4$ Hz, 1H), 5.00 (s, 2H), 4.44 (t, $J = 9.2$ Hz, 1H), 4.28 (dd, $J = 9.2, 5.2$ Hz, 1H), 4.05 (d, $J = 5.6$ Hz, 2H), 3.88 (dd, $J = 8.8, 5.2$ Hz, 1H), 2.41 (s, 3H), 2.32 (s, 3H), 1.11 (s, 9H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 156.3, 144.8, 139.3, 135.8, 134.6, 134.1, 133.5, 129.5, 129.3, 127.3, 120.1, 117.0, 114.3, 107.5, 86.5, 71.1, 66.3, 65.5, 63.4, 62.6, 34.9, 25.3, 21.5, 21.1; IR (neat): 2961, 2923, 2254(s), 1777(s), 1731, 1217, 1176, 580; HRESIMS Calcd for $[C_{29}H_{32}N_2NaO_5S]^+$ ($M + Na^+$) 543.1924, found 543.1926.


(*S*)-3-((2-((allyloxy)methyl)-6-chloro-1-tosyl-1*H*-indol-3-yl)ethynyl)-4-(*tert*-butyl)oxazolidin-2-one (5f)



5f

Pale yellow solid (mp 150-151°C). $[\alpha]_D^{20} = -30.5^\circ$ ($c = 1.0, \text{CHCl}_3$). ^1H NMR (400 MHz, CDCl_3) δ 8.14 (d, $J = 1.6$ Hz, 1H), 7.92 (d, $J = 8.4$ Hz, 2H), 7.50 (d, $J = 8.4$ Hz, 1H), 7.24 (dd, $J = 8.4, 1.6$ Hz, 1H), 7.20 (d, $J = 8.4$ Hz, 2H), 5.98 – 5.84 (m, 1H), 5.29 (dd, $J = 17.6, 1.6$ Hz, 1H), 5.19 (d, $J = 10.4$ Hz, 1H), 4.98 (d, $J = 1.6$ Hz, 2H), 4.44 (t, $J = 8.8$ Hz, 1H), 4.27 (dd, $J = 9.2, 5.2$ Hz, 1H), 4.04 (d, $J = 5.6$ Hz, 2H), 3.88 (dd, $J = 8.8, 5.2$ Hz, 1H), 2.34 (s, 3H), 1.10 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ 156.2, 145.2, 140.5, 135.4, 134.4, 134.1, 130.3, 129.7, 129.6, 127.3, 126.1, 119.9, 117.2, 115.8, 107.0, 87.0, 71.3, 66.2, 65.6, 62.6, 62.5, 34.9, 25.3, 21.5; IR (neat): 2967, 2261(s), 1174(s), 1371, 1179, 1137, 1071, 663, 585; HRESIMS Calcd for $[\text{C}_{28}\text{H}_{29}\text{ClN}_2\text{NaO}_5\text{S}]^+$ ($\text{M} + \text{Na}^+$) 563.1378, found 563.1375.


(S)-3-((2-((allyloxy)methyl)-5-bromo-1-tosyl-1*H*-indol-3-yl)ethynyl)-4-(*tert*-butyl)oxazolidin-2-one (5g)



5g

Pale yellow solid (mp 170-171°C). $[\alpha]_D^{20} = -10.5^\circ$ ($c = 1.0, \text{CHCl}_3$). ^1H NMR (400 MHz, CDCl_3) δ 7.98 (d, $J = 8.8$ Hz, 1H), 7.90 (d, $J = 8.0$ Hz, 2H), 7.69 (s, 1H), 7.42 (d, $J = 8.8$ Hz, 1H), 7.16 (d, $J = 8.4$ Hz, 2H), 5.98 – 5.83 (m, 1H), 5.29 (d, $J = 17.2$ Hz, 1H), 5.18 (d, $J = 10.4$ Hz, 1H), 4.98 (s, 2H), 4.43 (t, $J = 9.2$ Hz, 1H), 4.26 (dd, $J = 9.2, 5.2$ Hz, 1H), 4.05 (d, $J = 5.6$ Hz, 2H), 3.88 (dd, $J = 8.8, 5.2$ Hz, 1H), 2.29 (s, 3H), 1.08 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ 156.2, 145.2, 140.2, 135.2, 134.4, 134.3, 130.7, 129.5, 128.6, 127.2, 122.9, 117.2, 117.1, 116.0, 106.8, 87.0, 71.2, 66.1, 65.5, 62.4, 62.3, 34.8, 25.2, 21.4; IR (neat): 2963, 2257(s), 1771(s), 1445, 1372, 1247, 1178, 581; HRESIMS Calcd for $[\text{C}_{28}\text{H}_{29}\text{BrN}_2\text{NaO}_5\text{S}]^+$ ($\text{M} + \text{Na}^+$) 607.0873, found 607.0879.


methyl (S)-2-((allyloxy)methyl)-3-((4-(*tert*-butyl)-2-oxooxazolidin-3-yl)ethynyl)-1-tosyl-1*H*-indole-5-carboxylate (5h)



5h

Pale yellow solid (mp 150-151°C). $[\alpha]_D^{20} = -31.5^\circ$ (c = 1.0, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 8.27 (d, J = 1.2 Hz, 1H), 8.14 (d, J = 8.8 Hz, 1H), 8.01 (dd, J = 8.8, 1.6 Hz, 1H), 7.92 (d, J = 8.4 Hz, 2H), 7.17 (d, J = 8.4 Hz, 2H), 5.99 – 5.80 (m, 1H), 5.29 (ddd, J = 17.2, 3.2, 1.6 Hz, 1H), 5.18 (dd, J = 10.4, 1.6 Hz, 1H), 5.08 – 4.93 (m, 2H), 4.45 (t, J = 9.0 Hz, 1H), 4.27 (dd, J = 9.2, 5.2 Hz, 1H), 4.05 (d, J = 5.6 Hz, 2H), 3.95 – 3.83 (m, 4H), 2.30 (s, 3H), 1.10 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 166.8, 156.2, 145.3, 140.6, 138.2, 135.2, 134.3, 129.6, 128.9, 127.4, 126.8, 125.8, 122.5, 117.2, 114.3, 107.9, 87.1, 71.3, 66.2, 65.6, 62.5, 62.4, 52.1, 34.9, 25.2, 21.4; IR (neat): 2951, 2933, 2255(s), 1790(s), 1780(s), 1731, 1218, 1175, 580; HRESIMS Calcd for [C₃₀H₃₂N₂NaO₇S]⁺ (M + Na⁺) 587.1822, found 587.1829.

(S)-3-((2-((allyloxy)methyl)-6-methyl-1-tosyl-1*H*-indol-3-yl)ethynyl)-4-(*tert*-butyl)oxazolidin-2-one (5i)




5i

Pale yellow solid (mp 130-131°C). $[\alpha]_D^{20} = -22.7^\circ$ (c = 1.0, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 7.97 – 7.77 (m, 3H), 7.46 (d, J = 8.0 Hz, 1H), 7.18 (d, J = 8.4 Hz, 2H), 7.09 (d, J = 8.0 Hz, 1H), 6.01 – 5.81 (m, 1H), 5.29 (dd, J = 17.2, 1.6 Hz, 1H), 5.17 (dd, J = 10.4,

1.2 Hz, 1H), 5.08 – 4.88 (m, 2H), 4.43 (t, J = 9.2 Hz, 1H), 4.27 (dd, J = 9.2, 5.2 Hz, 1H), 4.04 (d, J = 5.6 Hz, 2H), 3.87 (dd, J = 8.8, 5.2 Hz, 1H), 2.48 (s, 3H), 2.32 (s, 3H), 1.11 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ 156.3, 144.8, 138.6, 136.2, 136.1, 135.8, 134.6, 129.5, 127.3, 126.8, 125.3, 119.9, 117.0, 114.7, 107.6, 86.5, 71.1, 66.2, 65.5, 63.4, 62.7, 34.9, 25.3, 22.1, 21.5; IR (neat): 2968, 2256(s), 1174(s), 1371, 1177, 662, 585; HRESIMS Calcd for $[\text{C}_{29}\text{H}_{32}\text{N}_2\text{NaO}_5\text{S}]^+$ ($\text{M} + \text{Na}^+$) 543.1924, found 543.1925.

***N*-(2-((allyl-1,1-*d*₂-oxy)methyl)-1-tosyl-1*H*-indol-3-yl)ethynyl)-*N*-methylmethanesulfonamide (1a')**




1,1-dideuteroallyl alcohol:^{3b}

Under an argon atmosphere, LiAlD_4 (0.52 g, 12.5 mmol) and anhydrous ether (20 mL) were added into a 50 mL flame-dried flask fitted with magnetic stirrer bar at -10 °C. Then, a solution of acryloyl chloride (1.5 mL, 17.8 mmol) in ether was added dropwise over 10 min. The resulting mixture was warmed to rt slowly and stirred for 10 h. The mixture was cooled to -10 °C and H_2O (1.0 mL) was slowly added over a 5 min. period. After stirring for another 15 min, 15% aqueous NaOH solution (1.0 mL) and then H_2O (1.0 mL) were added. The resulting slurry was stirred for 1 h and then filtered. The filtrate was dried over Na_2SO_4 . The solvent was removed carefully on a rotary evaporator (atmospheric pressure, 37 °C) to afford a colorless liquid, which was used in the next step without further purification.

propargyl 1,1-dideuteroallyl ether:


NaH (18 mmol, 0.43 g) was added to a mixture of the 1,1-dideuteroallyl alcohol (15 mmol, 0.90 g) and DMF (15 mL) at rt. After stirring at rt for 1 h, propargyl bromide (18 mmol, 2.15 g) was added. The reaction mixture was stirred for another 5 h at rt then quenched with a saturated aqueous solution of NH_4Cl (30 mL). The resulting solution was extracted with EtOAc (2*30 mL) and washed with brine (2*30 mL). The combined organic layers were dried over anhydrous MgSO_4 and concentrated under reduced pressure, and the residue was purified by chromatography on silica gel (eluent:

hexanes/ethyl acetate) to afford the desired propargyl 1,1-dideuteroallyl ether in 60% yield (0.88 g).



Compound **1a'** was prepared according to the above known procedures.¹⁻³ Pale yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.12 (d, *J* = 8.4 Hz, 1H), 7.93 (d, *J* = 8.4 Hz, 2H), 7.58 (d, *J* = 7.6 Hz, 1H), 7.44 – 7.32 (m, 1H), 7.31 – 7.24 (m, 1H), 7.18 (d, *J* = 8.0 Hz, 2H), 5.93 (dd, *J* = 17.2, 10.4 Hz, 1H), 5.31 (dd, *J* = 17.2, 1.6 Hz, 1H), 5.21 (dd, *J* = 10.4, 1.6 Hz, 1H), 5.01 (s, 2H), 3.33 (s, 3H), 3.14 (s, 3H), 2.33 (s, 3H); IR (neat): 2927, 2240(s), 1450, 1358(s), 1176, 1109, 997, 764; HRESIMS Calcd for [C₂₃H₂₂D₂N₂NaO₅S₂]⁺ (M + Na⁺) 497.1144, found 497.1152.

N-((2-(((allyl-2-*d*)oxy)methyl)-1-tosyl-1*H*-indol-3-yl)ethynyl)-*N*-methylmethanesulfonamide (**1a''**)




2-deuteroallyl alcohol:^{3d}

Under an argon atmosphere, LiAlD₄ (0.52 g, 12.5 mmol) and anhydrous ether (20 mL) were added into a 50 mL flame-dried flask fitted with magnetic stirrer bar at -10 °C. Then,


a solution of allyl alcohol (1.0 g, 17.8 mmol) in ether was added dropwise over 10 min. The resulting mixture was warmed to rt slowly and stirred for 24 h. The mixture was cooled to -10 °C and H₂O (1.0 mL) was slowly added over a 5 min. period. After stirring for another 15 min, 15% aqueous NaOH solution (1.0 mL) and then H₂O (1.0 mL) were added. The resulting slurry was stirred for 1 h and then filtered. The filtrate was dried over Na₂SO₄. The solvent was removed carefully on a rotary evaporator (atmospheric pressure, 37 °C) to afford a colorless liquid, which was used in the next step without further purification.

propargyl 2-deuteroallyl ether:

NaH (18 mmol, 0.43 g) was added to a mixture of the 2-deuteroallyl alcohol (15 mmol, 0.89 g) and DMF (15 mL) at rt. After stirring at rt for 1 h, propargyl bromide (18 mmol, 2.15 g) was added. The reaction mixture was stirred for another 5 h at rt then quenched with a saturated aqueous solution of NH₄Cl (30 mL). The resulting solution was extracted with EtOAc (2*30 mL) and washed with brine (2*30 mL). The combined organic layers were dried over anhydrous MgSO₄ and concentrated under reduced pressure, and the residue was purified by chromatography on silica gel (eluent: hexanes/ethyl acetate) to afford the desired propargyl 2-deuteroallyl ether in 60% yield (0.87 g).




Compound **1a''** was prepared according to the above known procedures.¹⁻³ Pale yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.13 (d, *J* = 8.4 Hz, 1H), 7.94 (d, *J* = 8.0 Hz, 2H), 7.59 (d, *J* = 7.6 Hz, 1H), 7.41 – 7.33 (m, 1H), 7.32 – 7.23 (m, 1H), 7.17 (d, *J* = 8.4 Hz, 2H), 6.00 – 5.87 (m, 0.1H), 5.31 (d, *J* = 1.6 Hz, 1H), 5.21 (s, 1H), 5.02 (s, 2H), 4.06 (s, 2H), 3.33 (s, 3H), 3.13 (s, 3H), 2.31 (s, 3H); IR (neat): 2920, 2230(s), 1359(s), 1275, 1260, 1176, 764, 749; HRESIMS Calcd for [C₂₃H₂₃DN₂O₅S₂]⁺ (M + Na⁺) 496.1082, found 496.1079.



General procedure for the synthesis of indole-fused bridged [4.2.1] lactones 2:

HNTf₂ (0.04 mmol, 11.2 mg) was added to a mixture of the ynamide **1** (0.20 mmol) and DCE (4.0 mL) at room temperature. Then, the reaction mixture was stirred at 40 °C and the progress of the reaction was monitored by TLC. The reaction typically took 24 h. Upon completion, the mixture was concentrated and the residue was purified by chromatography on silica gel (eluent: hexanes/ethyl acetate) to afford the desired indole-fused bridged [4.2.1] lactone **2**.

7-tosyl-4,5,6,7-tetrahydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one (2a**)**




2a

Compound **2a** was prepared in 77% yield (58.7 mg) according to the general procedure (Table 2, entry 1). Pale yellow solid (mp 190–191 °C). ¹H NMR (400 MHz, CDCl₃) δ

8.23 (d, $J = 8.0$ Hz, 1H), 7.54 (d, $J = 8.4$ Hz, 2H), 7.49 – 7.39 (m, 1H), 7.40 – 7.23 (m, 2H), 7.17 (d, $J = 8.4$ Hz, 2H), 5.09 (t, $J = 7.2$ Hz, 1H), 3.94 (dt, $J = 17.2, 4.4$ Hz, 1H), 3.84 (d, $J = 8.0$ Hz, 1H), 2.96 – 2.80 (m, 1H), 2.76 – 2.61 (m, 1H), 2.47 – 2.34 (m, 1H), 2.31 (s, 3H), 1.87 (d, $J = 12.4$ Hz, 1H), 1.84 – 1.75 (m, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 175.5, 145.1, 136.7, 136.3, 135.8, 129.9, 128.5, 126.2, 124.9, 123.9, 121.4, 117.7, 115.4, 78.4, 37.0, 35.9, 31.8, 21.6, 19.8; IR (neat): 2927, 1763(s), 1451, 1376, 1358, 1166, 1148, 974, 763; HRESIMS Calcd for $[\text{C}_{21}\text{H}_{19}\text{NNaO}_4\text{S}]^+$ ($\text{M} + \text{Na}^+$) 404.0927, found 404.0927.


4-allyl-9-tosyl-4,9-dihydropyrano[3,4-*b*]indol-3(1*H*)-one (2aa)



2aa

^1H NMR (400 MHz, CDCl_3) δ 8.11 (d, $J = 8.0$ Hz, 1H), 7.64 (d, $J = 8.4$ Hz, 2H), 7.47 – 7.34 (m, 2H), 7.33 – 7.17 (m, 3H), 5.85 – 5.64 (m, 2H), 5.55 – 5.41 (m, 1H), 4.96 – 4.81 (m, 2H), 4.08 – 3.96 (m, 1H), 2.93 – 2.80 (m, 1H), 2.75 – 2.63 (m, 1H), 2.35 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 169.9, 145.6, 137.0, 134.7, 132.2, 130.1, 127.9, 127.3, 126.4, 125.5, 124.1, 119.5, 118.9, 116.3, 114.5, 67.0, 39.2, 36.7, 21.6; IR (neat): 2994, 1769(s), 1758, 1382, 1245, 1057, 913, 747; HRESIMS Calcd for $[\text{C}_{21}\text{H}_{19}\text{NNaO}_4\text{S}]^+$ ($\text{M} + \text{Na}^+$) 404.0927, found 404.0927.

10-methyl-7-tosyl-4,5,6,7-tetrahydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one (2b)




2b

Compound **2b** was prepared in 65% yield (51.4 mg) according to the general procedure (Table 2, entry 2). Pale yellow solid (mp 195–196 °C). ^1H NMR (400 MHz, CDCl_3) δ

8.10 (d, $J = 8.4$ Hz, 1H), 7.57 – 7.48 (m, 2H), 7.24 (s, 1H), 7.17 (d, $J = 8.0$ Hz, 2H), 7.13 (dd, $J = 8.4, 1.2$ Hz, 1H), 5.09 (t, $J = 7.2$ Hz, 1H), 3.93 (dt, $J = 17.2, 4.4$ Hz, 1H), 3.82 (d, $J = 8.0$ Hz, 1H), 2.90 – 2.80 (m, 1H), 2.78 – 2.63 (m, 1H), 2.42 (s, 3H), 2.41 – 2.36 (m, 1H), 2.33 (s, 3H), 1.87 (d, $J = 12.4$ Hz, 1H), 1.85 – 1.77 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 175.5, 144.9, 136.8, 135.8, 134.6, 133.6, 129.9, 128.8, 126.2, 126.1, 121.4, 117.7, 115.2, 78.4, 36.9, 35.9, 31.8, 21.5, 21.2, 19.9; IR (neat): 2923, 2854, 1768(s), 1461, 1357, 1177, 1152, 1043, 744; HRESIMS Calcd for $[\text{C}_{22}\text{H}_{21}\text{NNaO}_4\text{S}]^+$ ($\text{M} + \text{Na}^+$) 418.1083, found 418.1080.


**10-methoxy-7-tosyl-4,5,6,7-tetrahydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one
(2c)**



2c

Compound **2c** was prepared in 66% yield (54.3 mg) according to the general procedure (Table 2, entry 3). Pale yellow solid (mp 200–201 °C). ^1H NMR (400 MHz, CDCl_3) δ 8.11 (d, $J = 9.2$ Hz, 1H), 7.54 – 7.47 (m, 2H), 7.17 (d, $J = 8.4$ Hz, 2H), 6.92 (dd, $J = 8.8, 2.4$ Hz, 1H), 6.87 (d, $J = 2.4$ Hz, 1H), 5.10 (t, $J = 7.2$ Hz, 1H), 3.92 (dt, $J = 17.2, 4.4$ Hz, 1H), 3.83 (s, 3H), 3.78 (d, $J = 8.0$ Hz, 1H), 2.93 – 2.77 (m, 1H), 2.76 – 2.65 (m, 1H), 2.47 – 2.35 (m, 1H), 2.33 (s, 3H), 1.87 (d, $J = 12.0$ Hz, 1H), 1.85 – 1.77 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 175.5, 156.9, 145.0, 137.5, 135.6, 130.9, 129.8, 129.6, 126.1, 121.7, 116.5, 113.6, 100.4, 78.4, 55.6, 36.9, 36.0, 31.7, 21.5, 19.9; IR (neat): 2923, 2852, 1773(s), 1475, 1458, 1356, 1150, 1087, 1042, 763, 748; HRESIMS Calcd for $[\text{C}_{22}\text{H}_{21}\text{NNaO}_5\text{S}]^+$ ($\text{M} + \text{Na}^+$) 434.1033, found 434.1034.


10-fluoro-7-tosyl-4,5,6,7-tetrahydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one (2d)



2d

Compound **2d** was prepared in 73% yield (58.3 mg) according to the general procedure (Table 2, entry 4). Pale yellow solid (mp 188–189 °C). ^1H NMR (400 MHz, CDCl_3) δ 8.26 – 8.13 (m, 1H), 7.53 (d, J = 8.4 Hz, 2H), 7.20 (d, J = 8.4 Hz, 2H), 7.11 (dd, J = 8.8, 2.8 Hz, 1H), 7.08 – 6.95 (m, 1H), 5.11 (t, J = 7.2 Hz, 1H), 3.93 (dt, J = 17.2, 4.0 Hz, 1H), 3.74 (d, J = 8.0 Hz, 1H), 2.99 – 2.79 (m, 1H), 2.77 – 2.63 (m, 1H), 2.48 – 2.37 (m, 1H), 2.35 (s, 3H), 1.89 (d, J = 12.4 Hz, 1H), 1.86 – 1.79 (m, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 175.2, 160.0 (d, J = 241.7 Hz), 145.4, 138.5, 135.5, 132.5, 130.0, 129.7 (d, J = 9.6 Hz), 126.1, 121.2 (d, J = 3.9 Hz), 116.7 (d, J = 9.1 Hz), 112.7 (d, J = 25.0 Hz), 103.5 (d, J = 24.4 Hz), 78.4, 36.8, 36.0, 31.6, 21.6, 20.0; IR (neat): 2922, 1773(s), 1458, 1376, 1358, 1265, 1176, 1150, 704; HRESIMS Calcd for $[\text{C}_{21}\text{H}_{18}\text{FNNaO}_4\text{S}]^+$ ($\text{M} + \text{Na}^+$) 422.0833, found 422.0836.

10-chloro-7-tosyl-4,5,6,7-tetrahydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one (2e)




2e

Compound **2e** was prepared in 66% yield (54.7 mg) according to the general procedure (Table 2, entry 5). Pale yellow solid (mp 184–185 °C). ^1H NMR (400 MHz, CDCl_3) δ 8.16 (d, J = 8.8 Hz, 1H), 7.54 (d, J = 8.4 Hz, 2H), 7.44 (d, J = 2.0 Hz, 1H), 7.31 – 7.14 (m, 3H), 5.11 (t, J = 7.2 Hz, 1H), 3.93 (dt, J = 17.2, 4.4 Hz, 1H), 3.77 (d, J = 8.0 Hz, 1H), 2.92 – 2.78 (m, 1H), 2.77 – 2.67 (m, 1H), 2.46 – 2.36 (m, 1H), 2.35 (s, 3H), 1.88 (d, J = 12.4 Hz, 1H), 1.85 – 1.77 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 175.1, 145.4, 138.3, 135.6, 134.6, 130.1, 129.8(0), 129.7(5), 126.2, 125.0, 120.7, 117.5, 116.5, 78.3, 36.8,

35.9, 31.6, 21.6, 19.9; IR (neat): 2923, 2852, 1769(s), 1450, 1377, 1355, 1159, 1043, 587; HRESIMS Calcd for $[C_{21}H_{18}ClNNaO_4S]^+$ ($M + Na^+$) 438.0537, found 438.0539.


10-bromo-7-tosyl-4,5,6,7-tetrahydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one (2f)



2f

Compound **2f** was prepared in 70% yield (67.5 mg) according to the general procedure (Table 2, entry 6). Pale yellow solid (mp 245–246 °C). 1H NMR (400 MHz, $CDCl_3$) δ 8.11 (d, $J = 8.8$ Hz, 1H), 7.60 (d, $J = 1.6$ Hz, 1H), 7.54 (d, $J = 8.4$ Hz, 2H), 7.41 (dd, $J = 8.8, 2.0$ Hz, 1H), 7.21 (d, $J = 8.0$ Hz, 2H), 5.11 (t, $J = 7.2$ Hz, 1H), 3.93 (dt, $J = 17.2, 4.4$ Hz, 1H), 3.77 (d, $J = 8.0$ Hz, 1H), 2.92 – 2.77 (m, 1H), 2.76 – 2.66 (m, 1H), 2.46 – 2.37 (m, 1H), 2.35 (s, 3H), 1.87 (d, $J = 12.4$ Hz, 1H), 1.85 – 1.74 (m, 1H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 175.1, 145.5, 138.1, 135.6, 135.0, 130.2, 130.1, 127.7, 126.2, 120.6, 120.5, 117.4, 116.8, 78.3, 36.9, 35.9, 31.6, 21.6, 19.9; IR (neat): 2292, 2850, 1768(s), 1450, 1375, 1355, 1157, 1088, 663, 584; HRESIMS Calcd for $[C_{21}H_{18}BrNNaO_4S]^+$ ($M + Na^+$) 482.0032, found 482.0039.

7-tosyl-10-(trifluoromethyl)-4,5,6,7-tetrahydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one (2g)




2g

Compound **2g** was prepared in 78% yield (70.0 mg) according to the general procedure (Table 2, entry 7). Pale yellow solid (mp 190–191 °C). 1H NMR (400 MHz, $CDCl_3$) δ 8.36 (d, $J = 8.8$ Hz, 1H), 7.76 (s, 1H), 7.63 – 7.52 (m, 3H), 7.30 – 7.19 (m, 2H), 5.13 (t, $J = 7.2$ Hz, 1H), 3.96 (dt, $J = 17.2, 4.4$ Hz, 1H), 3.88 (d, $J = 7.6$ Hz, 1H), 2.94 – 2.82 (m,

1H), 2.81 – 2.68 (m, 1H), 2.50 – 2.39 (m, 1H), 2.36 (s, 3H), 1.91 (d, J = 12.4 Hz, 1H), 1.89 – 1.78 (m, 1H); ^{13}C NMR (212.5 MHz, CDCl_3) δ 175.1, 145.7, 138.6, 137.7, 135.5, 130.2, 128.1, 126.3 (q, J = 31.6 Hz), 126.2, 124.4 (q, J = 270.3 Hz), 121.5 (q, J = 3.2 Hz), 120.9, 115.6, 115.3 (q, J = 3.9 Hz), 78.4, 36.9, 35.8, 31.5, 21.6, 19.8; IR (neat): 2922, 2850, 1770(s), 1379, 1325, 1168, 1122, 579; HRESIMS Calcd for $[\text{C}_{22}\text{H}_{18}\text{F}_3\text{NNaO}_4\text{S}]^+$ ($\text{M} + \text{Na}^+$) 472.0801, found 472.0799.


2-oxo-7-tosyl-1,2,4,5,6,7-hexahydro-1,4-methanooxocino[5,4-*b*]indole-10-carbonitrile (2h)



2h

Compound **2h** was prepared in 60% yield (48.7 mg) according to the general procedure (Table 2, entry 8). Pale yellow solid (mp 225–226 °C). ^1H NMR (400 MHz, CDCl_3) δ 8.35 (dd, J = 8.8, 0.8 Hz, 1H), 7.82 (d, J = 1.2 Hz, 1H), 7.62 – 7.53 (m, 3H), 7.25 (d, J = 8.0 Hz, 2H), 5.13 (t, J = 7.2 Hz, 1H), 3.93 (dt, J = 17.2, 4.4 Hz, 1H), 3.83 (d, J = 7.6 Hz, 1H), 2.92 – 2.70 (m, 2H), 2.48 – 2.38 (m, 1H), 2.37 (s, 3H), 1.92 (d, J = 12.4 Hz, 1H), 1.91 – 1.80 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 174.8, 146.0, 139.2, 137.9, 135.4, 130.3, 128.4, 127.7, 126.3, 122.6, 120.4, 119.0, 116.1, 107.4, 78.3, 36.7, 35.8, 31.5, 21.6, 19.9; IR (neat): 2924, 2226(s), 1769(s), 1459, 1380, 1357, 1173, 1153, 1087, 956, 668; HRESIMS Calcd for $[\text{C}_{22}\text{H}_{18}\text{N}_2\text{NaO}_4\text{S}]^+$ ($\text{M} + \text{Na}^+$) 429.0879, found 429.0884.


methyl 2-oxo-7-tosyl-1,2,4,5,6,7-hexahydro-1,4-methanooxocino[5,4-*b*]indole-10-carboxylate (2i)



2i

Compound **2i** was prepared in 79% yield (69.4 mg) according to the general procedure (Table 2, entry 9). Pale yellow solid (mp 191–192 °C). ¹H NMR (400 MHz, CDCl₃) δ 8.28 (d, *J* = 8.8 Hz, 1H), 8.20 (d, *J* = 0.8 Hz, 1H), 8.00 (dd, *J* = 8.8, 1.2 Hz, 1H), 7.57 (d, *J* = 8.4 Hz, 2H), 7.20 (d, *J* = 8.0 Hz, 2H), 5.11 (t, *J* = 6.8 Hz, 1H), 4.04 – 3.83 (m, 5H), 2.92 – 2.80 (m, 1H), 2.79 – 2.68 (m, 1H), 2.49 – 2.27 (m, 4H), 1.90 (d, *J* = 12.4 Hz, 1H), 1.89 – 1.77 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 175.1, 166.9, 145.5, 138.8, 138.1, 135.6, 130.1, 128.3, 126.2, 126.0, 125.8, 121.4, 119.9, 115.0, 78.3, 52.1, 36.9, 35.8, 31.6, 21.5, 19.8; IR (neat): 2924, 2851, 1773(s), 1718(s), 1274, 1160, 765; HRESIMS Calcd for [C₂₃H₂₁NNaO₆S]⁺ (M + Na⁺) 462.0982, found 462.0994.


9-methyl-7-tosyl-4,5,6,7-tetrahydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one (2j)



2j

Compound **2j** was prepared in 86% yield (68.0 mg) according to the general procedure (Table 2, entry 10). Pale yellow solid (mp 196–197 °C). ¹H NMR (400 MHz, CDCl₃) δ 8.05 (s, 1H), 7.53 (d, *J* = 8.4 Hz, 2H), 7.33 (d, *J* = 8.0 Hz, 1H), 7.18 (d, *J* = 8.0 Hz, 2H), 7.11 (d, *J* = 8.0 Hz, 1H), 5.09 (t, *J* = 7.2 Hz, 1H), 3.90 (dt, *J* = 17.2, 4.4 Hz, 1H), 3.81 (d, *J* = 7.6 Hz, 1H), 2.89 – 2.77 (m, 1H), 2.75 – 2.63 (m, 1H), 2.49 (s, 3H), 2.44 – 2.37 (m, 1H), 2.34 (s, 3H), 1.87 (d, *J* = 12.4 Hz, 1H), 1.86 – 1.76 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 175.5, 145.0, 136.8, 135.9(3), 135.8(6), 135.0, 129.9, 126.3, 126.1, 125.3, 121.4, 117.3, 115.6, 78.4, 36.9, 35.9, 31.8, 22.0, 21.5, 19.8; IR (neat): 2923, 2854, 1768(s), 1461, 1357, 1177, 1152, 1043, 744; HRESIMS Calcd for [C₂₂H₂₁NNaO₄S]⁺ (M + Na⁺) 418.1083, found 418.1080.


9-methoxy-7-tosyl-4,5,6,7-tetrahydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one (2k)



2k

Compound **2k** was prepared in 80% yield (65.8 mg) according to the general procedure (Table 2, entry 11). Pale yellow solid (mp 198–199 °C). ¹H NMR (500 MHz, CDCl₃) δ 7.81 (d, *J* = 2.0 Hz, 1H), 7.53 (d, *J* = 8.5 Hz, 2H), 7.32 (d, *J* = 8.5 Hz, 1H), 7.19 (d, *J* = 8.5 Hz, 2H), 6.92 (dd, *J* = 8.5, 2.0 Hz, 1H), 5.09 (t, *J* = 7.0 Hz, 1H), 3.94 – 3.81 (m, 4H), 3.78 (d, *J* = 8.0 Hz, 1H), 2.86 – 2.78 (m, 1H), 2.74 – 2.66 (m, 1H), 2.44 – 2.36 (m, 1H), 2.35 (m, 3H), 1.88 (d, *J* = 12.5 Hz, 1H), 1.84 – 1.76 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 175.5, 158.1, 145.1, 137.4, 135.8, 135.2, 129.9, 126.1, 122.5, 121.4, 118.2, 112.8, 100.1, 78.5, 55.8, 36.9, 36.0, 31.8, 21.6, 19.9; IR (neat): 2924, 2852, 1774(s), 1612, 1491, 1362, 1270, 1042, 992, 584; HRESIMS Calcd for [C₂₂H₂₁NaO₅S]⁺ (M + Na⁺) 434.1033, found 434.1034.

9-fluoro-7-tosyl-4,5,6,7-tetrahydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one (**2l**)




2l

Compound **2l** was prepared in 70% yield (55.9 mg) according to the general procedure (Table 2, entry 12). Pale yellow solid (mp 197–198 °C). ¹H NMR (400 MHz, CDCl₃) δ 7.99 (dd, *J* = 10.4, 2.0 Hz, 1H), 7.63 – 7.51 (m, 2H), 7.45 – 7.32 (m, 1H), 7.22 (d, *J* = 8.0 Hz, 2H), 7.12 – 6.99 (m, 1H), 5.11 (t, *J* = 7.2 Hz, 1H), 3.91 (dt, *J* = 17.2, 4.0 Hz, 1H), 3.80 (d, *J* = 7.6 Hz, 1H), 2.95 – 2.78 (m, 1H), 2.77 – 2.65 (m, 1H), 2.46 – 2.35 (m, 1H), 2.36 (s, 3H), 1.90 (d, *J* = 12.0 Hz, 1H), 1.89 – 1.78 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 175.3, 161.0 (d, *J* = 241.4 Hz), 145.4, 136.8 (d, *J* = 4.1 Hz), 136.4 (d, *J* = 12.6 Hz), 135.6, 130.1, 126.2, 124.8, 120.8, 118.4 (d, *J* = 9.9 Hz), 112.1 (d, *J* = 24.4 Hz), 102.9 (d, *J* = 29.4 Hz), 78.4, 36.8, 36.0, 31.7, 21.6, 19.9; IR (neat): 2824, 1773(s), 1363, 1275,

1261, 993, 749; HRESIMS Calcd for $[C_{21}H_{18}FNNaO_4S]^+$ ($M + Na^+$) 422.0833, found 422.0836.


9-chloro-7-tosyl-4,5,6,7-tetrahydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one (2m)



2m

Compound **2m** was prepared in 81% yield (67.2 mg) according to the general procedure (Table 2, entry 13). Pale yellow solid (mp 200-201 °C). 1H NMR (400 MHz, $CDCl_3$) δ 8.16 (d, $J = 8.8$ Hz, 1H), 7.54 (d, $J = 8.4$ Hz, 2H), 7.44 (d, $J = 2.0$ Hz, 1H), 7.30 – 7.25 (m, 1H), 7.20 (d, $J = 8.0$ Hz, 2H), 5.11 (t, $J = 7.2$ Hz, 1H), 3.93 (dt, $J = 17.2, 4.0$ Hz, 1H), 3.77 (d, $J = 8.0$ Hz, 1H), 2.90 – 2.79 (m, 1H), 2.76 – 2.67 (m, 1H), 2.46 – 2.37 (m, 1H), 2.35 (m, 3H), 1.88 (d, $J = 12.4$ Hz, 1H), 1.87 – 1.77 (m, 1H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 175.1, 145.5, 138.3, 135.6, 134.6, 130.1, 129.8(1), 129.7(5), 126.2, 125.0, 120.7, 117.5, 116.5, 78.3, 36.9, 35.9, 31.6, 21.6, 19.9; IR (neat): 2924, 1770(s), 1450, 1377, 1355, 1275, 1260, 764, 749; HRESIMS Calcd for $[C_{21}H_{18}ClNaO_4S]^+$ ($M + Na^+$) 438.0537, found 438.0539.

9-bromo-7-tosyl-4,5,6,7-tetrahydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one (2n)




2n

Compound **2n** was prepared in 80% yield (73.4 mg) according to the general procedure (Table 2, entry 14). Pale yellow solid (mp 245-246 °C). 1H NMR (400 MHz, $CDCl_3$) δ 8.44 (d, $J = 1.2$ Hz, 1H), 7.57 (d, $J = 8.4$ Hz, 2H), 7.40 (dd, $J = 8.4, 1.6$ Hz, 1H), 7.32 (d, $J = 8.4$ Hz, 1H), 7.23 (d, $J = 8.0$ Hz, 2H), 5.10 (t, $J = 7.2$ Hz, 1H), 3.89 (dt, $J = 17.2, 4.4$ Hz, 1H), 3.79 (d, $J = 8.0$ Hz, 1H), 2.87 – 2.67 (m, 2H), 2.46 – 2.37 (m, 1H), 2.36 (s, 3H),

1.89 (d, $J = 12.4$ Hz, 1H), 1.88 – 1.77 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 175.2, 145.5, 137.2, 136.9, 135.7, 130.1, 127.3, 127.1, 126.2, 120.9, 118.8, 118.5, 118.3, 78.4, 36.8, 35.9, 31.6, 21.6, 19.9; IR (neat): 2921, 2848, 1768(s), 1450, 1370, 1355, 1155, 584; HRESIMS Calcd for $[\text{C}_{21}\text{H}_{18}\text{BrNNaO}_4\text{S}]^+$ ($\text{M} + \text{Na}^+$) 482.0032, found 482.0039.


methyl 2-oxo-7-tosyl-1,2,4,5,6,7-hexahydro-1,4-methanooxocino[5,4-*b*]indole-9-carboxylate (2o)



2o

Compound **2o** was prepared in 70% yield (61.5 mg) according to the general procedure (Table 2, entry 15). Pale yellow solid (mp 187–188 °C). ^1H NMR (400 MHz, CDCl_3) δ 8.93 (s, 1H), 7.97 (dd, $J = 8.4, 1.2$ Hz, 1H), 7.58 (d, $J = 8.4$ Hz, 2H), 7.49 (d, $J = 8.4$ Hz, 1H), 7.20 (d, $J = 8.0$ Hz, 2H), 5.11 (t, $J = 7.2$ Hz, 1H), 4.02 – 3.96 (m, 1H), 3.95 (s, 3H), 3.86 (d, $J = 8.0$ Hz, 1H), 2.93 – 2.80 (m, 1H), 2.78 – 2.68 (m, 1H), 2.48 – 2.37 (m, 1H), 2.33 (s, 3H), 1.90 (d, $J = 12.4$ Hz, 1H), 1.89 – 1.79 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 175.2, 167.2, 145.5, 140.0, 135.6(4), 135.5(5), 131.9, 130.1, 126.6, 126.2, 125.0, 121.0, 117.4, 117.0, 78.3, 52.2, 36.8, 35.9, 31.5, 21.5, 20.0; IR (neat): 2952, 1777(s), 1716(s), 1435, 1423, 1166, 1090, 995, 736, 579; HRESIMS Calcd for $[\text{C}_{23}\text{H}_{21}\text{NNaO}_6\text{S}]^+$ ($\text{M} + \text{Na}^+$) 462.0982, found 462.0994.

8-methyl-7-tosyl-4,5,6,7-tetrahydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one (2p)




2p

Compound **2p** was prepared in 72% yield (56.9 mg) according to the general procedure (Table 2, entry 16). Pale yellow solid (mp 188–189 °C). ^1H NMR (400 MHz, CDCl_3) δ

7.23 – 7.17 (m, 1H), 7.17 – 7.09 (m, 4H), 7.07 (d, J = 8.0 Hz, 2H), 5.05 (t, J = 7.2 Hz, 1H), 3.63 – 3.48 (m, 2H), 2.95 – 2.81 (m, 1H), 2.70 (s, 3H), 2.68 – 2.54 (m, 1H), 2.40 – 2.33 (m, 1H), 2.32 (s, 3H), 1.76 – 1.67 (m, 1H), 1.65 (d, J = 12.4 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 174.8, 144.7, 140.9, 139.4, 133.2, 133.0, 130.2, 129.1, 128.9, 127.1, 126.3, 125.5, 115.4, 78.4, 36.6, 35.8, 31.5, 22.5, 21.6, 21.5; IR (neat): 2923, 2854, 1770(s), 1462, 1357, 1180, 1152, 1043, 754; HRESIMS Calcd for $[\text{C}_{22}\text{H}_{21}\text{NNaO}_4\text{S}]^+$ ($M + \text{Na}^+$) 418.1083, found 418.1080.


7-((4-bromophenyl)sulfonyl)-4,5,6,7-tetrahydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one (2q)



2q

Compound **2q** was prepared in 83% yield (73.8 mg) according to the general procedure (Table 2, entry 17). Pale yellow solid (mp 201-202 °C). ^1H NMR (400 MHz, CDCl_3) δ 8.19 (dd, J = 7.2, 1.2 Hz, 1H), 7.57 – 7.44 (m, 5H), 7.37 – 7.27 (m, 2H), 5.12 (t, J = 7.2 Hz, 1H), 3.92 (dt, J = 17.2, 4.4 Hz, 1H), 3.86 (d, J = 7.6 Hz, 1H), 2.97 – 2.83 (m, 1H), 2.80 – 2.67 (m, 1H), 2.51 – 2.37 (m, 1H), 1.90 (d, J = 12.4 Hz, 1H), 1.88 – 1.79 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 175.3, 137.4, 136.6, 136.2, 132.6, 129.2, 128.7, 127.5, 125.2, 124.3, 122.3, 117.9, 115.4, 78.3, 36.8, 35.9, 31.7, 19.9; IR (neat): 2921, 2850, 1768(s), 1450, 1375, 1355, 1157, 1088, 584; HRESIMS Calcd for $[\text{C}_{20}\text{H}_{16}\text{BrNNaO}_4\text{S}]^+$ ($M + \text{Na}^+$) 467.9876, found 467.9880.


7-(methylsulfonyl)-4,5,6,7-tetrahydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one (2r)



2r

Compound **2r** was prepared in 80% yield (48.8 mg) according to the general procedure (Table 2, entry 18). Pale yellow solid (mp 171–172 °C). ¹H NMR (400 MHz, CDCl₃) δ 8.08 – 7.99 (m, 1H), 7.60 – 7.51 (m, 1H), 7.38 – 7.29 (m, 2H), 5.16 (t, J = 7.2 Hz, 1H), 3.98 – 3.86 (m, 2H), 3.05 – 2.94 (m, 4H), 2.85 – 2.72 (m, 1H), 2.52 – 2.41 (m, 1H), 2.00 (d, J = 12.0 Hz, 1H), 1.99 – 1.89 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 175.6, 136.6, 135.8, 128.4, 125.0, 124.0, 121.1, 117.9, 114.7, 78.5, 41.2, 36.8, 35.9, 31.7, 19.5; IR (neat): 2927, 2853, 1763(s), 1451, 1358, 1204, 1148, 974, 747; HRESIMS Calcd for [C₁₅H₁₅NNaO₄S]⁺ (M + Na⁺) 328.0614, found 328.0618.


5-methyl-7-tosyl-4,5,6,7-tetrahydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one (2s)



2s

Compound **2s** was prepared in 63% yield (49.8 mg; dr = 4:1) according to the general procedure (Table 2, entry 19). Pale yellow solid (mp 185–186 °C). ¹H NMR (500 MHz, CDCl₃) δ 8.23 (d, J = 8.0 Hz, 1H), 7.54 (d, J = 8.5 Hz, 2H), 7.44 (d, J = 7.5 Hz, 1H), 7.37 – 7.24 (m, 2H), 7.18 (d, J = 8.0 Hz, 2H), 4.80 (d, J = 8.0 Hz, 1H), 3.91 (dd, J = 17.0, 4.0 Hz, 1H), 3.81 (d, J = 7.5 Hz, 1H), 2.78 – 2.68 (m, 1H), 2.66 – 2.56 (m, 1H), 2.34 (s, 3H), 2.08 – 1.96 (m, 1H), 1.88 (d, J = 12.5 Hz, 1H), 1.25 (d, J = 7.0 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 175.6, 145.1, 136.2, 135.7, 135.4, 129.9, 128.4, 126.1, 124.9, 123.9, 121.9, 117.6, 115.5, 84.3, 37.9, 37.5, 35.4, 27.7, 21.5(4), 21.4(9); IR (neat): 2923, 2850, 1766(s), 1451, 1364, 1170, 1106, 1088, 747, 579; HRESIMS Calcd for [C₂₂H₂₁NNaO₄S]⁺ (M + Na⁺) 418.1083, found 418.1083.


4-phenyl-7-tosyl-4,5,6,7-tetrahydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one (2t)



2t

Compound **2t** was prepared in 68% yield (62.2 mg) according to the general procedure (Table 2, entry 20). Pale yellow solid (mp 170-171 °C). ¹H NMR (400 MHz, CDCl₃) δ 8.27 (d, *J* = 8.0 Hz, 1H), 7.58 (d, *J* = 7.6 Hz, 2H), 7.48 (d, *J* = 7.2 Hz, 1H), 7.45 – 7.27 (m, 7H), 7.20 (d, *J* = 8.4 Hz, 2H), 4.19 – 3.93 (m, 2H), 3.05 – 2.86 (m, 1H), 2.80 – 2.65 (m, 1H), 2.50 – 2.30 (m, 5H), 2.25 – 2.13 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 174.5, 145.2, 136.2, 135.8, 129.9, 128.8, 128.5, 127.8, 126.2, 124.9, 123.9, 123.5, 121.3, 117.6, 115.4, 88.3, 43.3, 39.7, 37.7, 21.5, 21.0; IR (neat): 2922, 1774(s), 1449, 1363, 1192, 1171, 1090, 748; HRESIMS Calcd for [C₂₇H₂₃NNaO₄S]⁺ (M + Na⁺) 480.1240, found 480.1244.


9-methyl-4-phenyl-7-tosyl-4,5,6,7-tetrahydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one (**2u**)



2u

Compound **2u** was prepared in 75% yield (70.7 mg) according to the general procedure (Table 2, entry 21). Pale yellow solid (mp 205-206 °C). ¹H NMR (500 MHz, CDCl₃) δ 8.09 (s, 1H), 7.57 (d, *J* = 8.5 Hz, 2H), 7.44 – 7.29 (m, 6H), 7.21 (d, *J* = 8.0 Hz, 2H), 7.13 (d, *J* = 8.0 Hz, 1H), 4.08 – 3.98 (m, 2H), 3.00 – 2.81 (m, 1H), 2.77 – 2.63 (m, 1H), 2.51 (s, 3H), 2.42 – 2.35 (m, 4H), 2.32 (d, *J* = 12.5 Hz, 1H), 2.20 – 2.11 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 174.5, 145.2, 145.0, 136.7, 136.0, 135.4, 135.1, 129.9, 128.7, 127.7, 126.3, 126.1, 125.3, 123.5, 121.3, 117.2, 115.6, 88.3, 43.3, 39.8, 37.8, 22.0, 21.5, 21.0; IR (neat): 2921, 1775(s), 1448, 1363, 1171, 1148, 1090, 701, 582; HRESIMS Calcd for [C₂₈H₂₅NNaO₄S]⁺ (M + Na⁺) 494.1397, found 494.1400.


10-chloro-4-phenyl-7-tosyl-4,5,6,7-tetrahydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one (**2v**)



2v

Compound **2v** was prepared in 60% yield (58.9 mg) according to the general procedure (Table 2, entry 22). Pale yellow solid (mp 188-189 °C). ¹H NMR (500 MHz, CDCl₃) δ 8.19 (d, *J* = 9.0 Hz, 1H), 7.57 (d, *J* = 8.5 Hz, 2H), 7.46 (d, *J* = 2.0 Hz, 1H), 7.43 – 7.31 (m, 5H), 7.30 (dd, *J* = 9.0, 2.0 Hz, 1H), 7.23 (d, *J* = 8.0 Hz, 2H), 4.07 (dt, *J* = 17.0, 4.0 Hz, 1H), 3.99 (d, *J* = 8.0 Hz, 1H), 2.98 – 2.88 (m, 1H), 2.76 – 2.68 (m, 1H), 2.45 – 2.38 (m, 1H), 2.37 (s, 3H), 2.33 (d, *J* = 12.0 Hz, 1H), 2.23 – 2.13 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 174.1, 145.5, 145.0, 137.8, 135.5, 134.5, 130.1, 129.8, 129.7, 128.8, 127.9, 126.2, 125.0, 123.4, 120.5, 117.5, 116.5, 88.3, 43.2, 39.6, 37.7, 21.6, 21.1; IR (neat): 2922, 1777(s), 1451, 1364, 1171, 1090, 574; HRESIMS Calcd for [C₂₇H₂₂ClNNaO₄S]⁺ (M + Na⁺) 514.0850, found 514.0853.

10-bromo-4-phenyl-7-tosyl-4,5,6,7-tetrahydro-1,4-methanooxocino[5,4 *b*]indol-2(1*H*)-one (2w)




2w

Compound **2w** was prepared in 66% yield (70.6 mg) according to the general procedure (Table 2, entry 23). Pale yellow solid (mp 230-231 °C). ¹H NMR (500 MHz, CDCl₃) δ 8.14 (d, *J* = 9.0 Hz, 1H), 7.62 (d, *J* = 2.0 Hz, 1H), 7.57 (d, *J* = 8.5 Hz, 2H), 7.46 – 7.30 (m, 6H), 7.23 (d, *J* = 8.5 Hz, 2H), 4.07 (dt, *J* = 17.0, 4.0 Hz, 1H), 3.99 (d, *J* = 8.0 Hz, 1H), 2.97 – 2.87 (m, 1H), 2.75 – 2.68 (m, 1H), 2.46 – 2.38 (m, 1H), 2.37 (s, 3H), 2.33 (d, *J* = 12.5 Hz, 1H), 2.22 – 2.14 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 174.0, 145.5, 145.0, 137.7, 135.6, 135.0, 130.1, 128.8, 127.9, 127.7, 126.2, 123.4, 120.5, 120.4, 117.5, 116.9, 88.3, 43.3, 39.6, 37.7, 21.6, 21.1; IR (neat): 2291, 1777(s), 1450, 1378, 1359, 1192, 1168,

1090, 590; HRESIMS Calcd for $[C_{27}H_{22}BrNNaO_4S]^+$ ($M + Na^+$) 558.0345, found 558.0356.


4-(*p*-tolyl)-7-tosyl-4,5,6,7-tetrahydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one (2x)



2x

Compound **2x** was prepared in 64% yield (60.3 mg) according to the general procedure (Table 2, entry 24). Pale yellow solid (mp 200-201 °C). 1H NMR (400 MHz, $CDCl_3$) δ 8.27 (d, $J = 7.6$ Hz, 1H), 7.58 (d, $J = 8.4$ Hz, 2H), 7.53 – 7.44 (m, 1H), 7.40 – 7.12 (m, 8H), 4.16 – 3.98 (m, 2H), 3.03 – 2.87 (m, 1H), 2.78 – 2.64 (m, 1H), 2.49 – 2.27 (m, 8H), 2.22 – 2.07 (m, 1H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 174.6, 145.1, 142.4, 137.5, 136.3, 135.8, 129.9, 129.4, 128.5, 126.2, 125.0, 123.9, 123.5, 121.4, 117.7, 115.5, 88.4, 43.4, 39.8, 37.8, 21.5, 21.0; IR (neat): 2921, 1770(s), 1450, 1365, 1171, 1150, 1090, 701, 575; HRESIMS Calcd for $[C_{28}H_{25}NNaO_4S]^+$ ($M + Na^+$) 494.1397, found 494.1400.

4-(4-chlorophenyl)-7-tosyl-4,5,6,7-tetrahydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one (2y)




2y

Compound **2y** was prepared in 61% yield (59.9 mg) according to the general procedure (Table 2, entry 25). Pale yellow solid (mp 190-191 °C). 1H NMR (400 MHz, $CDCl_3$) δ 8.26 (dd, $J = 7.2, 0.4$ Hz, 1H), 7.58 (d, $J = 8.4$ Hz, 2H), 7.51 – 7.44 (m, 1H), 7.40 – 7.28 (m, 6H), 7.20 (d, $J = 8.0$ Hz, 2H), 4.15 – 4.01 (m, 2H), 3.02 – 2.82 (m, 1H), 2.74 – 2.60 (m, 1H), 2.43 – 2.26 (m, 5H), 2.23 – 2.07 (m, 1H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 174.2, 145.2, 143.6, 136.2, 136.1, 135.8, 133.7, 130.0, 129.0, 128.4, 126.2, 125.0, 123.9, 121.1,

117.6, 115.5, 87.8, 43.3, 39.6, 37.7, 21.6, 20.9; IR (neat): 2930, 1780(s), 1450, 1360, 1171, 1090, 585; HRESIMS Calcd for $[C_{27}H_{22}ClNNaO_4S]^+$ ($M + Na^+$) 514.0850, found 514.0853.


4-methyl-7-tosyl-4,5,6,7-tetrahydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one (2z)



2z

Compound **2z** was prepared in 67% yield (52.9 mg) according to the general procedure (Table 2, entry 26). Pale yellow solid (mp 221–222 °C). 1H NMR (400 MHz, $CDCl_3$) δ 8.26 (d, $J = 7.6$ Hz, 1H), 7.57 (d, $J = 8.0$ Hz, 2H), 7.47 (d, $J = 7.2$ Hz, 1H), 7.38 – 7.25 (m, 2H), 7.20 (d, $J = 8.4$ Hz, 2H), 4.06 – 3.93 (m, 2H), 2.90 – 2.78 (m, 1H), 2.50 – 2.40 (m, 1H), 2.35 (s, 3H), 2.30 – 2.22 (m, 1H), 1.93 (d, $J = 12.4$ Hz, 1H), 1.88 – 1.77 (m, 1H), 1.59 (s, 3H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 175.0, 145.1, 136.3, 136.2, 135.7, 129.9, 128.5, 126.2, 124.8, 123.8, 121.3, 117.6, 115.4, 86.0, 43.1, 38.2, 38.1, 29.1, 21.6, 20.8; IR (neat): 2923, 2851, 1768(s), 1451, 1364, 1170, 1106, 1088, 748, 579; HRESIMS Calcd for $[C_{22}H_{21}NNaO_4S]^+$ ($M + Na^+$) 418.1083, found 418.1080.

1,4,5,6-tetrahydro-2*H*-1,4-methanooxocino[5,4-*b*]benzofuran-2-one (4a)




4a

Compound **4a** was prepared in 61% yield (27.8 mg) according to the general procedure. Pale yellow solid (mp 154–155 °C). 1H NMR (400 MHz, $CDCl_3$) δ 7.56 – 7.47 (m, 1H), 7.44 – 7.36 (m, 1H), 7.32 – 7.17 (m, 2H), 5.15 (t, $J = 7.2$ Hz, 1H), 3.81 (d, $J = 7.6$ Hz, 1H), 3.18 – 2.98 (m, 2H), 2.87 – 2.76 (m, 1H), 2.51 – 2.40 (m, 1H), 2.03 (d, $J = 12.4$ Hz, 1H), 2.00 – 1.89 (m, 1H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 175.5, 154.5, 153.4, 127.6, 123.9, 122.8, 118.1, 115.2, 110.9, 78.3, 37.2, 34.9, 30.0, 22.0; IR (neat): 2948, 1768(s),

1453, 1274, 1258, 1155, 1040, 749; HRESIMS Calcd for $[C_{14}H_{12}NaO_3]^+$ ($M + Na^+$) 251.0679, found 251.0679.

1-tosyl-4,7,8,9-tetrahydro-4,7-methanooxocino[5,4-*b*]pyrrol-5(1*H*)-one (4b)




4b

Compound **4b** was prepared in 66% yield (43.7 mg) according to the general procedure. Pale yellow oil. 1H NMR (400 MHz, $CDCl_3$) δ 7.61 (d, $J = 8.4$ Hz, 2H), 7.29 (d, $J = 8.4$ Hz, 2H), 7.24 (d, $J = 3.2$ Hz, 1H), 6.16 (d, $J = 3.6$ Hz, 1H), 5.01 (t, $J = 7.2$ Hz, 1H), 3.55 – 3.38 (m, 2H), 2.67 – 2.56 (m, 1H), 2.53 – 2.39 (m, 4H), 2.34 – 2.23 (m, 1H), 1.88 (d, $J = 12.4$ Hz, 1H), 1.79 – 1.66 (m, 1H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 175.9, 145.3, 135.9, 130.2, 129.7, 126.8, 125.8, 121.3, 111.9, 78.4, 39.3, 37.4, 31.6, 21.6, 18.9; IR (neat):

2923, 2851, 1768(s), 1451, 1364, 1170, 1106, 1088, 748, 579; HRESIMS Calcd for $[C_{17}H_{17}NNaO_4S]^+$ ($M + Na^+$) 354.0770, found 354.0779.


8,9-dimethoxy-1,4,5,6-tetrahydro-2*H*-1,4-methanobenzo[*d*]oxocin-2-one (4c)



4c

Compound **4c** was prepared in 54% yield (26.8 mg) according to the general procedure. Pale yellow solid (mp 241–242 °C). 1H NMR (400 MHz, $CDCl_3$) δ 6.69 (s, 1H), 6.68 (s, 1H), 5.06 (t, $J = 7.2$ Hz, 1H), 3.85 (s, 3H), 3.84 (s, 3H), 3.54 (d, $J = 8.8$ Hz, 1H), 3.18 – 3.06 (m, 1H), 2.78 – 2.60 (m, 2H), 2.40 – 2.29 (m, 1H), 1.92 (d, $J = 12.4$ Hz, 1H), 1.90 – 1.80 (m, 1H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 177.3, 147.5, 147.2, 131.3, 131.1, 114.7, 113.5, 78.7, 56.0, 55.9, 46.9, 38.2, 33.4, 29.1; IR (neat): 2936, 1766(s), 1515, 1453, 1276,


1252, 1103, 749; HRESIMS Calcd for $[C_{14}H_{16}NaO_4]^+$ ($M + Na^+$) 271.0941, found 271.0943.



General procedure for the synthesis of chiral bridged [4.2.1] lactones **2-ent:**

HNTf₂ (0.06 mmol, 16.8 mg) was added to a mixture of the chiral ynamide **5** (0.20 mmol), water (0.30 mmol, 5.4 uL) and dry DCE (2.0 mL) at room temperature. Then, the reaction mixture was stirred at 30 °C and the progress of the reaction was monitored by TLC. The reaction typically took 1 h. Upon completion, the mixture was concentrated and the residue was purified by chromatography on silica gel (eluent: hexanes/ethyl acetate) to afford the desired chiral bridged [4.2.1] lactone **2-ent**.


(1*S*,4*S*)-7-tosyl-4,5,6,7-tetrahydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one (2a-ent**)**



2a-ent

Compound **2a-ent** was prepared in 55% yield (41.9 mg) according to the general procedure (Table 3, entry 1). 95% ee (determined by HPLC: Chiralcel OD-H Column, 10/90 *i*-PrOH/hexane, 1.0 mL/min, 200 nm; TR = 27.21 min (minor), 33.53 min (major)).


(1*S*,4*S*)-10-methyl-7-tosyl-4,5,6,7-tetrahydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one (2b-ent**)**



2b-ent

Compound **2b-ent** was prepared in 50% yield (35.9 mg) according to the general procedure (Table 3, entry 2). 99% ee (determined by HPLC: Chiralcel OD-H Column, 15/85 *i*-PrOH/hexane, 1.3 mL/min, 200 nm; TR = 15.57 min (major), 21.21 min (minor)).


(1*S*,4*S*)-10-chloro-7-tosyl-4,5,6,7-tetrahydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one (2e-ent**)**



2e-ent

Compound **2e-ent** was prepared in 52% yield (43.2 mg) according to the general procedure (Table 3, entry 3). 91% ee (determined by HPLC: Chiralcel OD-H Column, 5/95 *i*-PrOH/hexane, 1.3 mL/min, 200 nm; TR = 33.00 min (minor), 36.73 min (major)).


(1*S*,4*S*)-10-bromo-7-tosyl-4,5,6,7-tetrahydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one (2f-ent**)**



2f-ent

Compound **2f-ent** was prepared in 53% yield (48.6 mg) according to the general procedure (Table 3, entry 4). 98% ee (determined by HPLC: Chiralcel OD-H Column, 5/95 *i*-PrOH/hexane, 1.3 mL/min, 200 nm; TR = 34.94 min (minor), 39.54 min (major)).


methyl (1*S*,4*S*)-2-oxo-7-tosyl-1,2,4,5,6,7-hexahydro-1,4-methanooxocino[5,4-*b*]indole-10-carboxylate (2i-ent**)**



2i-ent

Compound **2i-ent** was prepared in 51% yield (44.8 mg) according to the general procedure (Table 3, entry 5). $[\alpha]_D^{20} = -40.7^\circ$ (c = 1.0, CHCl₃). 92% ee (determined by HPLC: Chiralcel IA Column, 10/90 *i*-PrOH/hexane, 2.0 mL/min, 200 nm; TR = 17.49 min (minor), 21.05 min (major)).


(1*S*,4*S*)-9-methyl-7-tosyl-4,5,6,7-tetrahydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one (2j-ent**)**



2j-ent

Compound **2j-ent** was prepared in 42% yield (33.2 mg) according to the general procedure (Table 3, entry 6). 98% ee (determined by HPLC: Chiralcel OD-H Column, 15/85 *i*-PrOH/hexane, 1.3 mL/min, 200 nm; TR = 31.00 min (minor), 34.39 min (major)).


(1*R*,4*R*)-10-methyl-7-tosyl-4,5,6,7-tetrahydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one (2a-ent'**)**



2a-ent'


Compound **2a-ent'** was prepared in 56% yield (42.7 mg) according to the general procedure (Table 3, entry 7). $[\alpha]_D^{20} = +10.7^\circ$ ($c = 1.0$, CHCl₃). 96% ee (determined by HPLC: Chiralcel OD-H Column, 10/90 *i*-PrOH/hexane, 1.0 mL/min, 200 nm; TR = 25.17 min (major), 32.09 min (minor)).

4,5,6,7-tetrahydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one (2ab)



Compound **2ab** was prepared in 75% yield (34.1 mg) according to the known procedures (0.2 mmol scale).⁵ Pale yellow solid (mp 143–144 °C). ¹H NMR (400 MHz, DMSO) δ 11.04 (s, 1H), 7.54 (d, *J* = 7.2 Hz, 1H), 7.31 – 7.25 (m, 1H), 7.12 – 6.67 (m, 2H), 5.14 (t, *J* = 7.2 Hz, 1H), 3.95 (d, *J* = 7.6 Hz, 1H), 3.00 – 2.69 (m, 3H), 2.39 – 2.26 (m, 1H), 1.99 – 1.91 (m, 1H), 1.89 (d, *J* = 12.4 Hz, 1H); ¹³C NMR (125 MHz, DMSO) δ 177.7, 136.7, 135.1, 127.9, 121.6, 119.8, 118.1, 111.7, 111.6, 79.2, 38.1, 36.5, 31.7, 22.3; IR (neat): 3270, 2923, 2851, 1760(s), 1515, 1455, 1360, 1172, 952, 742; HRESIMS Calcd for [C₁₄H₁₃NNaO₂]⁺ (M + Na⁺) 250.0838, found 250.0839.


7-tosyl-1,2,4,5,6,7-hexahydro-1,4-methanooxocino[5,4-*b*]indol-2-ol (2ac)



Compound **2ac** was prepared in 91% yield (69.7 mg; dr > 10/1) according to the known procedures (0.2 mmol scale).⁶ Pale yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.25 (dd, *J* = 7.2, 1.2 Hz, 1H), 7.54 (d, *J* = 8.0 Hz, 2H), 7.48 – 7.41 (m, 1H), 7.34 – 7.22 (m, 2H), 7.16 (d, *J* = 8.0 Hz, 2H), 5.24 (d, *J* = 2.8 Hz, 1H), 4.87 (t, *J* = 7.2 Hz, 1H), 3.62 (dt, *J* =


17.2, 4.4 Hz, 1H), 3.46 (d, J = 6.4 Hz, 1H), 3.12 (s, 1H), 3.05 – 2.90 (m, 1H), 2.72 – 2.59 (m, 1H), 2.33 (s, 3H), 2.23 – 2.09 (m, 1H), 1.67 (d, J = 12.0 Hz, 1H), 1.60 – 1.48 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 144.7, 137.2, 136.5, 136.1, 129.7, 129.6, 126.2, 124.4, 123.6, 123.3, 117.7, 115.5, 102.9, 78.6, 41.3, 35.6, 32.2, 21.5, 20.9; IR (neat): 2930, 2851, 1750(s), 1450, 1250, 1170, 568; HRESIMS Calcd for $[\text{C}_{21}\text{H}_{21}\text{NNaO}_4\text{S}]^+$ ($M + \text{Na}^+$) 406.1083, found 406.1095.

7-tosyl-1,2,4,5,6,7-hexahydro-1,4-methanooxocino[5,4-*b*]indole (2ad)




Compound **2ad** was prepared in 99% yield (72.7 mg) according to the known procedures (0.2 mmol scale).⁷ Pale yellow solid (mp 150–151 °C). ¹H NMR (400 MHz, CDCl₃) δ 8.24 (dd, *J* = 7.2, 1.6 Hz, 1H), 7.54 (d, *J* = 8.4 Hz, 2H), 7.43 – 7.36 (m, 1H), 7.32 – 7.20 (m, 2H), 7.14 (d, *J* = 8.4 Hz, 2H), 4.69 (t, *J* = 7.6 Hz, 1H), 4.12 (dd, *J* = 7.6, 5.6 Hz, 1H), 3.86 (d, *J* = 7.6 Hz, 1H), 3.65 (dt, *J* = 16.8, 4.4 Hz, 1H), 3.56 (t, *J* = 6.0 Hz, 1H), 3.13 – 2.95 (m, 1H), 2.41 – 2.22 (m, 4H), 2.19 – 2.08 (m, 1H), 1.73 (d, *J* = 11.6 Hz, 1H), 1.58 – 1.43 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 144.5, 137.0, 136.3, 136.0, 129.6, 129.5, 127.1, 126.1, 124.0, 123.4, 117.3, 115.5, 77.2, 75.6, 38.7, 34.0, 32.1, 21.4, 20.7; IR (neat): 2923, 1451, 1376, 1361, 1176, 1089, 1060, 748, 579; HRESIMS Calcd for [C₂₁H₂₁NNaO₃S]⁺ (M + Na⁺) 390.1134, found 390.1141.

7-tosyl-4,7-dihydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one (2ae)



Compound **2ae** was prepared in 95% yield (72.0 mg) according to the known procedures (0.2 mmol scale).⁸ Pale yellow solid (mp 187–188 °C). ¹H NMR (400 MHz, CDCl₃) δ 8.26 (d, *J* = 8.4 Hz, 1H), 7.73 (dd, *J* = 12.0, 0.8 Hz, 1H), 7.68 – 7.48 (m, 3H), 7.46 – 7.29 (m, 2H), 7.16 (d, *J* = 8.0 Hz, 2H), 6.45 – 6.22 (m, 1H), 5.09 (t, *J* = 7.2 Hz, 1H), 4.07 (d, *J* = 7.2 Hz, 1H), 2.85 – 2.67 (m, 1H), 2.31 (s, 3H), 2.14 – 1.97 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 172.9, 145.2, 137.1, 135.0, 132.9, 129.8, 128.9, 128.5, 126.7, 126.3, 124.6, 123.3, 122.9, 119.0, 115.8, 73.7, 36.1, 27.0, 21.5; IR (neat): 2922, 1763(s), 1449, 1364, 1275, 1261, 1172, 764, 749; HRESIMS Calcd for [C₂₁H₁₇NNaO₄S]⁺ (M + Na⁺) 402.0770, found 402.0777.


(7-hydroxy-5-tosyl-5,6,7,8,9,10-hexahydrocyclohepta[b]indol-10-yl)(phenyl)methanone (2af)



PhLi (0.24 mmol, 1.2 equiv) was slowly added to the mixture of **2a** (0.20 mmol, 76.3 mg) in dry THF (4.0 mL) under N₂ at -40 °C. The mixture was stirred at -40 °C for 2 h, and then stirred at -20 °C for another 10 h. Upon completion, the mixture was quenched by the saturated ammonium chloride and extracted with EtOAc (3 × 10 mL). The combined extracts were dried with MgSO₄, and the solvent was removed under reduced pressure. The residue was purified by chromatography on silica gel (eluent: hexanes/ethyl acetate) to afford the desired **2af** in 60% yield (55.1 mg). Pale yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.22 (d, *J* = 8.4 Hz, 1H), 8.08 – 7.93 (m, 2H), 7.65 – 7.54 (m, 3H), 7.51 – 7.41 (m, 2H), 7.26 – 7.13 (m, 5H), 5.11 (dd, *J* = 5.2, 4.0 Hz, 1H), 4.07 – 3.93 (m, 1H), 3.75 – 3.63 (m, 1H), 3.19 – 3.00 (m, 1H), 2.60 – 2.49 (m, 1H), 2.34 (s, 3H), 2.26 – 2.12 (m, 1H), 2.03 – 1.88 (m, 1H), 1.60 – 1.47 (m, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 199.0, 144.6, 141.0, 136.3, 136.1(2), 136.0(8), 133.3, 129.9, 129.8, 128.9, 128.3, 126.2, 124.2, 123.5, 119.9, 117.4, 115.6, 69.5, 40.4, 37.7, 35.6, 21.6, 21.3; IR (neat): 2924, 2853, 1774(s),


1612, 1491, 1362, 1170, 1042, 662, 584; HRESIMS Calcd for $[C_{27}H_{25}NNaO_4S]^+$ ($M + Na^+$) 482.1397, found 482.1396.

(8*S*,10*S*)-10-(hydroxymethyl)-5-tosyl-5,6,7,8,9,10-hexahydrocyclohepta[*b*]indol-8-ol (2ag)




Compound **2ag** was prepared in 68% yield (52.4 mg) according to the above procedure (0.2 mmol scale). $[\alpha]_D^{20} = -80.5^\circ$ ($c = 1.0$, CHCl₃). 97% ee (determined by HPLC: Chiralcel AD-H Column, 5/95 *i*-PrOH/hexane, 2.0 mL/min, 200 nm; TR = 37.54 min (minor), 40.93 min (major)). Pale yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.21 (d, $J = 7.6$ Hz, 1H), 7.56 (d, $J = 8.4$ Hz, 2H), 7.41 – 7.32 (m, 1H), 7.31 – 7.20 (m, 2H), 7.17 (d, $J = 8.4$ Hz, 2H), 4.34 – 4.20 (m, 1H), 3.82 (d, $J = 6.4$ Hz, 2H), 3.47 (s, 1H), 3.41 – 3.27 (m, 2H), 3.24 – 3.09 (m, 1H), 2.38 – 2.22 (m, 4H), 2.06 – 1.92 (m, 2H), 1.91 – 1.75 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 144.6, 139.3, 136.5, 136.1, 130.3, 129.7, 126.2, 124.2, 123.6, 122.2, 117.7, 115.4, 69.9, 65.1, 36.0, 35.1, 34.0, 21.5, 21.0; IR (neat): 3300, 2933, 1530, 1218, 1175, 580; HRESIMS Calcd for $[C_{21}H_{23}NNaO_4S]^+$ ($M + Na^+$) 408.1240, found 408.1242.

(*S*)-(8-oxo-5-tosyl-5,6,7,8,9,10-hexahydrocyclohepta[*b*]indol-10-yl)methyl 4-nitrobenzoate (2ah) **4-**




Compound **2ah** was prepared in 46% yield (24.5 mg, 2 steps) according to the above procedure (0.1 mmol scale). $[\alpha]_D^{20} = -65.5^\circ$ ($c = 1.0$, CHCl_3). 97% ee (determined by HPLC: Chiralcel OD-H Column, 20/80 *i*-PrOH/hexane, 2.0 mL/min, 200 nm; TR = 25.95 min (minor), 31.98 min (major)). Pale yellow solid (mp 201–202 °C). ^1H NMR (400 MHz, CDCl_3) δ 8.32 – 8.17 (m, 3H), 8.11 – 7.98 (m, 2H), 7.62 – 7.53 (m, 3H), 7.42 – 7.26 (m, 2H), 7.18 (d, $J = 8.1$ Hz, 2H), 4.67 (dd, $J = 11.2, 5.6$ Hz, 1H), 4.25 (dd, $J = 11.2, 8.8$ Hz, 1H), 3.87 – 3.78 (m, 1H), 3.69 – 3.57 (m, 1H), 3.52 – 3.40 (m, 1H), 3.12 – 2.94 (m, 2H), 2.81 – 2.69 (m, 1H), 2.68 – 2.56 (m, 1H), 2.33 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 209.5, 164.4, 150.6, 145.1, 137.2, 136.5, 136.0, 135.0, 130.7, 129.9, 129.5, 126.2, 125.1, 123.9, 123.5, 119.1, 118.2, 115.5, 67.1, 43.2(4), 43.1(5), 32.3, 21.6, 21.5; IR (neat): 2933, 1750(s), 1738(s), 1520(s), 1325, 1215, 1120, 586; HRESIMS Calcd for $[\text{C}_{28}\text{H}_{24}\text{N}_2\text{NaO}_7\text{S}]^+$ ($\text{M} + \text{Na}^+$) 555.1196, found 555.1199.

methyl 7-methoxy-5-tosyl-5,6,7,8,9,10-hexahydrocyclohepta[*b*]indole-10-carboxylate (2ai)



Compound **2ai** was prepared in 20% yield (17.1 mg; d.r. > 20:1) according to the general procedure. Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 8.22 (dd, $J = 7.2, 0.8$ Hz, 1H), 7.63 – 7.54 (m, 2H), 7.36 – 7.30 (m, 1H), 7.29 – 7.22 (m, 2H), 7.17 (d, $J = 8.0$ Hz, 2H), 4.10 (dd, $J = 5.2, 3.2$ Hz, 1H), 3.67 – 3.61 (m, 4H), 3.59 – 3.50 (m, 1H), 3.38 (s, 3H), 3.02 – 2.91 (m, 1H), 2.74 – 2.62 (m, 1H), 2.34 (s, 3H), 2.17 – 2.06 (m, 1H), 1.72 – 1.58 (m, 2H); ^{13}C NMR (125 MHz, CDCl_3) δ 172.8, 144.7, 139.7, 136.2, 130.2, 129.8, 126.3, 124.3, 123.6, 119.4, 117.7, 115.3, 78.8, 56.2, 52.1, 37.7, 34.4, 31.2, 21.6, 21.3; IR (neat): 2994, 1769(s), 1758, 1375, 1245, 1056, 913, 743; HRESIMS Calcd for $[\text{C}_{23}\text{H}_{25}\text{NNaO}_5\text{S}]^+$ ($\text{M} + \text{Na}^+$) 450.1346, found 548.0153.

7-tosyl-4,5,6,7-tetrahydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one-5,5-*d*₂ (2a')




2a'

Compound **2a'** was prepared in 74% yield (56.7 mg) according to the general procedure.

¹H NMR (400 MHz, CDCl₃) δ 8.24 (d, *J* = 8.0 Hz, 1H), 7.55 (d, *J* = 8.4 Hz, 2H), 7.49 – 7.42 (m, 1H), 7.36 – 7.24 (m, 2H), 7.18 (d, *J* = 8.0 Hz, 2H), 5.09 (d, *J* = 8.0 Hz, 1H), 3.94 (d, *J* = 17.2 Hz, 1H), 3.85 (d, *J* = 8.0 Hz, 1H), 2.85 (d, *J* = 17.2 Hz, 1H), 2.78 – 2.65 (m, 1H), 2.33 (s, 3H), 1.88 (d, *J* = 12.4 Hz, 1H); IR (neat): 2922, 1785(s), 1449, 1363, 1274, 1261, 764, 749; HRESIMS Calcd for [C₂₁H₁₇D₂NNaO₄S]⁺ (M + Na⁺) 406.1053, found 406.1055.

7-tosyl-4,5,6,7-tetrahydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one-4-*d* (2a'')




2a''

Compound **2a''** was prepared in 72% yield (55.0 mg) according to the general procedure.

¹H NMR (400 MHz, CDCl₃) δ 8.24 (d, *J* = 7.6 Hz, 1H), 7.55 (d, *J* = 8.4 Hz, 2H), 7.49 – 7.42 (m, 1H), 7.36 – 7.25 (m, 2H), 7.18 (d, *J* = 8.0 Hz, 2H), 5.11 (t, *J* = 7.2 Hz, 0.1H), 3.96 (dt, *J* = 17.2, 4.4 Hz, 1H), 3.85 (d, *J* = 8.0 Hz, 1H), 2.95 – 2.79 (m, 1H), 2.77 – 2.65 (m, 1H), 2.47 – 2.36 (m, 1H), 2.33 (s, 3H), 1.88 (d, *J* = 12.0 Hz, 1H), 1.85 – 1.76 (m, 1H); IR (neat): 2922, 2851, 1773(s), 1449, 1363, 1275, 1171, 763, 749; HRESIMS Calcd for [C₂₁H₁₈DNNaO₄S]⁺ (M + Na⁺) 405.0990, found 405.0996.


1-allyl-6-tosyl-1,4,5,6-tetrahydro-2*H*-oxepino[4,5-*b*]indol-2-one (4ga)



4ga

Compound **4ga** was prepared in 42% yield (33.2 mg) according to the general procedure. Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 8.21 (dd, $J = 8.0, 0.8$ Hz, 1H), 7.60 (d, $J = 8.4$, 2H), 7.40 – 7.31 (m, 2H), 7.29 (dd, $J = 7.6, 1.2$ Hz, 1H), 7.20 (d, $J = 8.0$, 2H), 6.00 – 5.80 (m, 1H), 5.24 – 5.07 (m, 2H), 4.85 (td, $J = 12.8, 1.6$ Hz, 1H), 4.53 (dt, $J = 12.8, 4.0$ Hz, 1H), 4.30 (dd, $J = 9.6, 6.4$ Hz, 1H), 3.66 (dd, $J = 18.8, 2.0$ Hz, 1H), 3.43 – 3.25 (m, 1H), 2.87 – 2.62 (m, 2H), 2.35 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 171.9, 145.3, 136.4, 135.6, 133.8, 133.6, 130.1, 128.9, 126.3, 125.2, 123.8, 118.4, 118.1, 115.6, 114.8, 64.5, 45.2, 38.9, 29.3, 21.5; IR (neat): 2924, 1732(s), 1454, 1358, 1173, 1151, 1089, 575; HRESIMS Calcd for $[\text{C}_{22}\text{H}_{21}\text{NNaO}_4\text{S}]^+$ ($\text{M} + \text{Na}^+$) 418.1083, found 418.1083.

4-allylisochroman-3-one (4ha)



4ha


Compound **4ha** was prepared in 85% yield (32.0 mg) according to the general procedure. Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.38 – 7.20 (m, 4H), 5.93 – 5.81 (m, 1H), 5.41 (d, 1H, $J = 14.0$ Hz), 5.28 (d, 1H, $J = 14.0$ Hz), 5.17 – 5.09 (m, 2H), 3.70 (t, 1H, $J = 6.8$ Hz), 2.87 – 2.66 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 172.2, 134.2, 134.0, 131.4, 128.6, 127.2, 126.6, 124.6, 118.1, 69.5, 45.3, 34.2; IR (neat): 3076, 2924, 1744 (s), 1641, 1489, 1462, 1385, 1234, 1146, 1047, 913, 747; HRESIMS Calcd for $[\text{C}_{12}\text{H}_{12}\text{NaO}_2]^+$ ($\text{M} + \text{Na}^+$) 211.0730, found 211.0732.

Reference:

1. a) J. Zheng, Z. Li, W. Wu, H. Jiang, *Org. Lett.* **2016**, *18*, 6232; b) A. Arcadi, G. Bianchi, F. Marinelli, *Synthesis* **2004**, *4*, 610.
2. a) C. Shu, L. Li, X.-Y. Xiao, Y.-F. Yu, Y.-F. Ping, J.-M. Zhou, L.-W. Ye, *Chem. Commun.* **2014**, *50*, 8689; b) F. Pan, S. Liu, C. Shu, R.-K. Lin, Y.-F. Yu, J.-M. Zhou, L.-W. Ye, *Chem. Commun.* **2014**, *50*, 10726; c) N. S. Kumar, E. M. Dullaghan, B. B. Finlay, H. Gong, N. E. Reiner, J. J. P. Selvam, L. M. Thorson, S. Campbell, N. Vitko, A. R. Richardson, R. Zoraghi, R. N. Young, *Bioorg. Med. Chem.* **2014**, *22*, 1708; d) M. Yu, Y. Xie, C. Xie, Y. Zhang, *Org. Lett.* **2012**, *14*, 2164; e) M. Garzon, P. W. Davies, *Org. Lett.* **2014**, *16*, 4850; f) Y. Pan, G.-W. Chen, C.-H. Shen, W. He, L.-W. Ye, *Org. Chem. Front.* **2016**, *3*, 491.
3. a) X. Wu, Z. Chen, Y.-B. Bai, V. M. Dong, *J. Am. Chem. Soc.* **2016**, *138*, 12013; b) L.-L. Mao, C.-C. Li, Q. Yang, M.-X. Cheng, S.-D. Yang, *Chem. Commun.* **2017**, *53*, 4473; c) S. Hirano, R. Tanaka, H. Urabe, F. Sato, *Org. Lett.* **2004**, *6*, 727; d) C. Gryparis, C. Efe, C. Raptis, I. N. Lykakis, M. Stratakis, *Org. Lett.* **2012**, *14*, 2956.
4. J. Liu, Z. Fang, Q. Zhang, Q. Liu, X. Bi, *Angew. Chem. Int. Ed.* **2013**, *52*, 6953.
5. C. Zheng, J. J. Chen, R. Fan, *Org. Lett.* **2014**, *16*, 816.
6. K. Miyashita, T. Tsunemi, T. Hosokawa, M. Ikejiri, T. Imanishi, *J. Org. Chem.* **2008**, *73*, 5360.
7. N. Sakai, T. Moriya, K. Fujii, T. Konakahara, *Synthesis* **2008**, *21*, 3533.
8. L. Li, X.-M. Chen, Z.-S. Wang, B. Zhou, X. Liu, X. Lu, L.-W. Ye, *ACS Catal.* **2017**, *7*, 4004.

7-tosyl-4,5,6,7-tetrahydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one (2a). CCDC

Number = 1831051



Bond precision: C-C = 0.0020 Å Wavelength=1.54184

Cell: a=9.07481 (16) b=15.0220 (2) c=12.7620 (2)
alpha=90 beta=99.1959 (16) gamma=90

Temperature: 100 K

	Calculated	Reported
Volume	1717.38 (5)	1717.38 (5)
Space group	P 21/n	P 1 21/n 1
Hall group	-P 2yn	-P 2yn
Moiety formula	C21 H19 N O4 S	C21 H19 N O4 S
Sum formula	C21 H19 N O4 S	C21 H19 N O4 S
Mr	381.43	381.43
Dx, g cm ⁻³	1.475	1.475
Z	4	4
Mu (mm ⁻¹)	1.924	1.924
F000	800.0	800.0
F000'	803.67	
h,k,lmax	10,17,15	10,17,15
Nref	3062	3057
Tmin, Tmax	0.794, 0.825	0.567, 1.000
Tmin'	0.749	

Correction method= # Reported T Limits: Tmin=0.567 Tmax=1.000
AbsCorr = MULTI-SCAN


Data completeness= 0.998 Theta(max) = 67.074

R(reflections)= 0.0396 (2966) wR2(reflections)= 0.1068 (3057)

S = 1.024 Npar= 245

5-methyl-7-tosyl-4,5,6,7-tetrahydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one (2s).

CCDC Number = 1831053



Bond precision: C-C = 0.0030 Å Wavelength=0.71073

Cell: a=13.780 (3) b=9.3801 (19) c=14.410 (3)
alpha=90 beta=92.893 (4) gamma=90

Temperature: 273 K

	Calculated	Reported
Volume	1860.2 (7)	1860.2 (6)
Space group	P 21/n	P 1 21/n 1
Hall group	-P 2yn	-P 2yn
Moiety formula	C ₂₂ H ₂₁ N O ₄ S	C ₂₂ H ₂₁ N O ₄ S
Sum formula	C ₂₂ H ₂₁ N O ₄ S	C ₂₂ H ₂₁ N O ₄ S
Mr	395.46	395.46
Dx, g cm ⁻³	1.412	1.412
Z	4	4
μ (mm ⁻¹)	0.204	0.204
F000	832.0	832.0
F000'	832.88	
h, k, lmax	17, 12, 18	17, 12, 18
Nref	4265	4240
Tmin, Tmax	0.980, 0.980	
Tmin'	0.980	


Correction method= Not given

Data completeness= 0.994 Theta(max) = 27.485

R(reflections)= 0.0530 (3644) wR2(reflections)= 0.1365 (4240)

S = 1.070 Npar= 255

9-methyl-4-phenyl-7-tosyl-4,5,6,7-tetrahydro-1,4-methanooxocino[5,4-*b*]indol-2(1*H*)-one (2u). CCDC Number = 1831054



Bond precision: C-C = 0.0041 Å Wavelength=1.54184

Cell: a=12.3488 (2) b=9.82302 (14) c=19.2566 (4)
alpha=90 beta=108.549 (2) gamma=90

Temperature: 100 K

	Calculated	Reported
Volume	2214.53 (7)	2214.53 (8)
Space group	P 21/c	P 1 21/c 1
Hall group	-P 2ybc	-P 2ybc
Moiety formula	C28 H25 N O4 S	C28 H25 N O4 S
Sum formula	C28 H25 N O4 S	C28 H25 N O4 S
Mr	471.55	471.55
Dx,g cm ⁻³	1.414	1.414
Z	4	4
μ (mm ⁻¹)	1.606	1.606
F000	992.0	992.0
F000'	996.15	
h,k,lmax	14,11,22	14,11,21
Nref	3907	3742
Tmin, Tmax	0.825, 0.852	0.744, 1.000
Tmin'	0.725	

Correction method= # Reported T Limits: Tmin=0.744 Tmax=1.000
AbsCorr = MULTI-SCAN



Data completeness= 0.958 Theta(max) = 66.583

R(reflections) = 0.0479 (3502) wR2(reflections) = 0.1277 (3742)

S = 1.156 Npar= 309

(S)-(8-oxo-5-tosyl-5,6,7,8,9,10-hexahydrocyclohepta[b]indol-10-yl)methyl nitrobenzoate (2ah). CCDC Number = 1864037

4-



Bond precision: C-C = 0.0080 Å

Wavelength=1.54184

Cell: a=9.68936 (19) b=16.6569 (4) c=15.2343 (3)
alpha=90 beta=94.933 (2) gamma=90

Temperature: 100 K

	Calculated	Reported
Volume	2449.63 (9)	2449.63 (9)
Space group	P 21	P 1 21 1
Hall group	P 2yb	P 2yb
Moiety formula	C28 H24 N2 O7 S	C28 H24 N2 O7 S
Sum formula	C28 H24 N2 O7 S	C28 H24 N2 O7 S
Mr	532.55	532.55
Dx, g cm-3	1.444	1.444
Z	4	4
Mu (mm-1)	1.629	1.629
F000	1112.0	1112.0
F000'	1116.84	
h, k, lmax	11,19,18	11,19,18
Nref	8746 [4539]	6188
Tmin, Tmax		0.532, 1.000
Tmin'		




Correction method= # Reported T Limits: Tmin=0.532 Tmax=1.000
AbsCorr = MULTI-SCAN

Data completeness= 1.36/0.71 Theta(max) = 67.079




R(reflections) = 0.0570 (5742) wR2(reflections) = 0.1593 (6188)

S = 1.026 Npar= 687


Compound 2a-*ent*




Compound 2b-*ent*



Compound 2e-*ent*






No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount n.a.	Type
1	31.65	n.a.	945.708	1459.033	49.18	n.a.	BMB*
2	36.60	n.a.	751.863	1507.930	50.82	n.a.	BMB*
Total:			1697.571	2966.963	100.00	0.000	






No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount n.a.	Type
1	33.00	n.a.	55.668	78.538	4.45	n.a.	BMB*
2	36.73	n.a.	814.805	1686.126	95.55	n.a.	BMB*
Total:			870.473	1764.664	100.00	0.000	




Compound 2f-*ent*






Compound 2i-*ent*






Compound 2j-*ent*





Compound 2a-*ent*'




Compound 2ag



Compound 2ah




No.	Ret.Time min	Peak Name	Height mAU	Area mAU·min	Rel.Area %	Amount n.a.	Type
1	26.91	n.a.	242.256	394.451	50.08	n.a.	BMB*
2	32.48	n.a.	199.536	393.236	49.92	n.a.	BMB*
Total:			441.792	787.688	100.00	0.000	





No.	Ret.Time min	Peak Name	Height mAU	Area mAU·min	Rel.Area %	Amount n.a.	Type
1	25.95	n.a.	0.040	2.070	1.56	n.a.	BMB*
2	31.98	n.a.	68.642	130.905	98.44	n.a.	BMB*
Total:			68.683	132.975	100.00	0.000	


No.	Ret.Time min	Peak Name	Height mAU	Area mAU·min	Rel.Area %	Amount n.a.	Type
1	25.67	n.a.	0.087	0.017	0.00	n.a.	BMB*
2	31.24	n.a.	551.958	1050.901	100.00	n.a.	BMB*
Total:			552.044	1050.917	100.00	0.000	


after recrystallization








































<8.238
<8.216
<7.957
<7.936
<7.846
<7.609
<7.587
<7.260
<7.221
<7.200


5.979
5.965
5.952
5.939
5.922
5.909
5.896
5.882
5.337
5.333
5.294
5.290
5.229
5.203
5.031




4.071
4.057
—3.355
—3.147

—2.346









8.265
8.168
8.146
8.045
8.023
8.019
7.944
7.923



7.260
7.199
7.179

5.974
5.960
5.947
5.934
5.917
5.904
5.890
5.876
5.332
5.328
5.324
5.289
5.285
5.281
5.219
5.216
5.193
5.190
5.012

4.068
4.065
4.057
4.054
3.929

-3.350
-3.149

-2.329



—166.79

—145.33
—140.83
—138.18
—135.24
—134.33
—129.62
—128.80
—127.35
—126.88
—125.80
—122.32
—117.23
—114.36

—107.74

—89.63
—77.32
—77.00
—76.68
—71.24

—62.38



—59.90


—52.10


—39.16


—37.04


—21.45














































144.36
142.02
137.79
136.14
134.44
131.71
129.98
129.28
127.18
126.56
124.65
117.91
117.01
-110.34


-90.00
77.32
77.00
76.68
-71.25
-64.54
-60.72


-39.12
-36.85
-22.11
-21.41









































































































3e






















3h


























































































2aa








— 175.50

— 144.94


— 136.76
— 135.83
— 134.61
— 133.57
— 129.85
— 128.78
— 126.24
— 126.10
— 121.36
— 117.65
— 115.18


— 78.42
— 77.32
— 77.00
— 76.68

— 36.92
— 35.86
— 31.75
— 21.50
— 21.22
— 19.87



2b





— 175.49

— 156.93

— 144.98

— 137.51
— 135.61
— 130.88
— 129.84
— 129.64
— 126.08
— 121.67

— 116.52

— 113.63



— 100.35


— 78.44
— 77.32
— 77.00
— 76.68

— 55.63

— 36.93
— 35.96
— 31.72

— 21.51
— 19.94





-175.21

-160.98

-159.06

-145.35

~138.53

~135.50

~132.51

~130.00

~129.71

~129.63

~126.13

~121.21

~121.18

~116.70

~116.62

~112.76

~112.56

~103.62

~103.43

~78.37

~77.25

~77.00

~76.75



~36.83


~36.01

~31.62

~21.55

~19.98





-175.09


-145.44

>138.25
>135.55
>134.62
<130.05
<129.80
<129.75
>126.15
>125.00
>120.65
>117.51
>116.49


<78.33
<77.32
<77.00
<76.68

>36.83
>35.89
>31.60

-21.55
-19.91



2e



<8.124
 <8.102
 7.598
 7.548
 7.527
 7.422
 7.400
 7.395
 7.260
 7.216
 7.196

5.125
 5.107
 5.089



3.963
 3.952
 3.941
 3.920
 3.898
 3.778
 3.758

2.874
 2.855
 2.843
 2.831
 2.812
 2.735
 2.724
 2.705


2.416
 2.405
 2.390

1.859
 1.834
 1.825

1.798
 1.788



2f




—175.07

— 145. 47


78.33
77.32
77.00
76.68


36. 86
35. 86
31. 60





21.56






2f









-174.76

-145.97


\ 139.18
/\ 137.92
/\ 135.43
\ 130.27
\ 128.43
\ 127.72
/\ 126.27
/\ 122.58
/\ 120.36
/\ 119.02
/\ 116.05

-107.43


\ 78.28
/\ 77.32
/\ 77.00
/\ 76.68

\ 36.70
/\ 35.84
-\ 31.47

\ 21.58
-\ 19.90




2h





8.291
 8.269
 8.204
 8.202
 8.015
 8.012
 7.993
 7.990
 7.578
 7.557
 7.260
 7.215
 7.195

5.132
 5.115
 5.097



2i







-8.054

7.545
7.524
7.336
7.316
7.260
7.195
7.175
7.123
7.103

5.107
5.089
5.071

3.932
3.922
3.911
3.889
3.879
3.868
3.821
3.802
2.839
2.827
2.718
2.707
2.698
2.689
2.492
2.416
2.401
2.390
2.379
2.364
1.859
1.845
1.834
1.813
1.806
1.804
1.797
1.776
1.766



0.97

2.01
1.07
2.05
1.00

1.00




1.03
0.98


1.01
1.04
3.06
1.06
3.06


0.96
1.07


9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 -0.5


f1 (ppm)
























—8.929

7.979
7.976
7.958
7.955

7.591
7.570
7.496
7.210

7.190

5.127
5.109
5.091

4.002
3.992
3.981
3.954
3.872
3.852



2.899
2.880
2.868
2.856
2.837
2.748
2.737
2.728
2.717
2.432
2.410
2.395
2.333
1.917
1.886
1.876
1.854
1.847
1.819
1.808

∫

∫
∫
∫

∫

∫
∫
∫
∫
∫
∫



—175.16

—167.16



—145.46
—140.01
—135.64
—135.55
—131.88
—130.06
—126.60
—126.24
—124.97
—121.03
—117.42
—117.00

78.31
77.32
77.00
76.68

—52.17

—36.79
—35.88
—31.50


—21.50
—20.00



7.260
7.222
7.204
7.185
7.158
7.141
7.137
7.121
7.102
7.077
7.057

5.064
5.046
5.028

3.608
3.592
3.588
3.583
3.560
3.549
3.539
2.904
2.885
2.873
2.861
2.842
2.704
2.631
2.620
2.611
2.601
2.340
2.321
1.741
1.729
1.710
1.704
1.701
1.695
1.674
1.661
1.631



2p

1.01
4.04
2.07

1.00


2.00


1.08
3.02
1.10
0.96
3.02


1.01
0.99


8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 -0.5 -1.0

f1 (ppm)











—175.64




~136.60
~135.80
~128.42
~125.02
~123.98
~121.11
~117.89
~114.74


78.50
77.32
77.00
76.68


~41.24
~36.81
~35.92
~31.69


—19.50






























—174.08
—145.49
—144.96
—137.80
—135.54
—134.53
—130.09
—129.84
—129.67
—128.80
—127.86
—126.19
—125.04
—123.43
—120.51







—88.29
—77.25
—77.00
—76.75


—43.23
—39.57
—37.72




—21.56
—21.06





























—129.92
—126.16
—124.84
—123.82
—117.66
—115.41

—43.12
—38.19
—38.17
—29.10
—21.53
—20.81



2z





— 175.50


~ 154.45
~ 153.37

~ 127.62
~ 123.93
~ 122.76
— 118.12
— 115.24
~ 110.92


~ 78.33
~ 77.32
~ 77.00
~ 76.68

— 37.17
— 34.91
— 30.01

— 22.03



4a



—22.03


—30.04

—34.90


—37.21


—78.27


—118.10
—122.75
—123.92



4a







— 7.260

6.694

6.675

5.076

5.058

5.041

3.849

3.837

3.549

3.527

3.131

3.126

3.123

3.114

3.091

2.738

2.707

2.660

2.619

2.336

2.332

1.940

1.909

1.887


1.878

1.853


1.843


1.818

1.809



4c





~114.68
~113.54

-78.65


~55.95
~55.92

-46.92


-38.19

-33.37

-29.10



4c



—11.037



ʃ

ʃ ʃ ʃ

ʃ

ʃ ʃ ʃ

0.99

1.01
0.97
2.01




1.00

1.02

3.04
1.00
0.99
1.06


12.5 12.0 11.5 11.0 10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -0.5 -1.0

f1 (ppm)






2ab (DMSO)

f1 (ppm)




f1 (ppm)








— 129.65
— 126.15
— 124.32
— 123.52
— 117.61
— 115.53
— 102.85
— 78.60
— 41.27
— 35.53
— 32.11
— 21.48
— 20.85



2ac








~129.59
~126.14
~124.05
~123.35
~117.28
~115.54


~77.25
~75.68


~38.77
~34.01
~32.13


~21.45
~20.74



2ad









-145.21


77.32
77.00
76.68
73.70



-36.10
-26.99
-21.51




2ae












2af


















































2ai
NOE
600 MHz, CDCl₃




8.249
8.229
7.561
7.540
7.467
7.447
7.344
7.341
7.326
7.323
7.306
7.301
7.297
7.281
7.279
7.260
7.190
7.170

5.105
5.085

3.960
3.917
3.859
3.839

2.872
2.829
2.750
2.730
2.719
2.711
2.700
2.680
2.330

1.898
1.867



$2a'$

0.96
1.97
1.01
2.52
2.00

0.99


0.99
0.95

1.00
1.00



3.00
0.96

9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -0.5

f1 (ppm)



8.225
 8.223
 8.205
 8.202
 7.612
 7.590
 7.356
 7.352
 7.299
 7.296
 7.280
 7.277
 7.260
 7.213
 7.212
 7.192
 5.956
 5.953
 5.930
 5.911
 5.905
 5.894
 5.888
 5.866
 5.869
 5.218
 5.215
 5.172
 5.168



4ga

